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ABSTRACT 
 
The overall goal of this research is to understand roles of gut microbiota 
metabolites and adipocyte transcription factor (TF) network in health and disease by 
developing systematic analysis methods. As microbiota can perform diverse 
biotransformation reactions, the spectrum of metabolites present in the gastrointestinal 
(GI) tract is extremely complex but only a handful of bioactive microbiota metabolites 
have been identified. We developed a metabolomics workflow that integrates in silico 
discovery with targeted mass spectrometry. A computational pathway analysis where 
microbiota metabolisms are modeled as a single metabolic network is utilized to predict 
a focused set of targets for multiple reaction monitoring (MRM) analysis. We validated 
our methodology by predicting, quantifying in murine cecum and feces and 
characterizing tryptophan (TRP)-derived metabolites as ligands for the aryl hydrocarbon 
receptor.  
The adipocyte process of lipid droplet accumulation and differentiation is 
regulated by multiple TFs that function together in a network. Although individual TF 
activation is previously reported, construction of an integrated network has been limited 
due to different measurement conditions. We developed an integrated network model of 
key TFs - PPAR, C/EBP, CREB, NFAT, FoxO1, and SREBP-1c - underlying 
adipocyte differentiation. A hypothetic model was determined based on literature, and 
stochastic simulation algorithm (SSA) was applied to simulate TF dynamics. TF 
activation profiles at different stages of differentiation were measured using 3T3-L1 
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reporter cell lines where binding of a TF to its DNA binding element drives expression 
of the Gaussia luciferase gene. Reaction trajectories calculated by SSA showed good 
agreement with experimental measurement. The TF model was further validated by 
perturbing dynamics of CREB using forskolin, and comparing the predicted response 
with experimental data.  
We studied the molecular recognition mechanism underlying anti-inflammatory 
function of a bacterial metabolite, indole in DC2.4 cells. The indole treatment attenuated 
the fraction of cells that were producing the pro-inflammatory cytokine, TNFα and 
knockdown of nuclear receptor related 1 (Nurr1; NR4A2) resulted in less indole-derived 
suppression of TNFα production. The first discovery of NR4A2 as a molecular mediator 
of the endogenous metabolite, indole is expected to provide a new strategy for treatment 
of inflammatory disorders.  
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CHAPTER I 
INTRODUCTION 
 
1.1 BACKGROUND 
 The human gastrointestinal tract is colonized by ~10
14
 bacteria belonging to 
~1,000 species that are collectively termed the gut microbiota (1). The gut microbiota 
have been classically known to be important in two main capacities - the digestion of 
dietary molecules and the generation of energy from fermentation of indigestible 
carbohydrates to short-chain fatty acids (2). Recent studies have shown that the intestinal 
microbiota is a “super organ” that mediates a wide range of functions including innate 
and adaptive immunity, inflammation, cell proliferation, and communication with the 
gut epithelium and distant organs (3). Alterations in the microbiota composition and/or 
function (dysbiosis) are increasingly correlated to several disorders, including several 
inflammatory diseases of the gut such as inflammatory bowel disease (IBD) and colitis 
(4, 5), as well as obesity, insulin resistance and type 2 diabetes (T2D) (6, 7). The effects 
of dysbiosis are not localized to the GI tract alone but are seen systemically as well as 
studies have associated several allergies (8, 9) and autism (10) to intestinal microbiota 
dysbiosis. Increasing evidence shows that the functional outputs of the microbiota (i.e., 
metabolites) are important modulators of function in the host. For example, conversion 
of choline into methylamines and trimethylamine by the microbiota causes non-alcoholic 
fatty liver disease (NAFLD) (11) and cardiovascular diseases (12).  
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 Obesity is one of the most common diseases that have been strongly associated 
with microbiota dysbiosis. Obesity correlates with complications of several metabolic 
disorders (e.g., insulin resistance and T2D) and increases risk for many other diseases 
such as NAFLD, atherosclerosis, and certain cancers. Development of the obesity and 
metabolic disorders is a complex process and associated with pathways which connect 
metabolism and immune systems (13). Obesity is characterized by an increase in body 
fat mass, specifically in that of white adipose tissue (WAT) (14). Expansion of the body 
fat mass can occur either due to an increase in the number of adipocytes and/or an 
increase in size of adipocytes. The increase of adipocyte cell size is an important 
component of the increase in adipose tissue mass (15). Adipocyte enlargement arises as 
a result of genetic or environmental conditions that progressively increase lipid loading. 
The enzymes mediating adipocyte lipid accumulation and utilization are regulated 
through the temporally coordinated action of several transcription factors (16, 17). 
Therefore, it is important to understand the dynamics and interaction between different 
members of the regulatory network for modulating complex phenotypes such as lipid 
balance in adipocytes. Phylogenetic (16S rRNA) sequencing and metabolomics analysis 
have shown that the composition and metabolite profile of the intestinal microbiota are 
significantly altered in obese subjects (18, 19). The microbiota in obese subjects or 
animals are able to extract more energy from diet (20), and interact with epithelial host 
cells to control energy storage and expenditure (21). 
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1.2 MOTIVATION  
 In the United States, IBD is one of the five most prevalent gastrointestinal 
disease burdens and an overall care cost is more than $1.7 billion. Each year, there are 
more than 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 
patients due to IBD (http://www.cdc.gov/ibd/). Several studies have established a strong 
correlation between intestinal inflammatory disease such as Crohn’s disease and 
dysbiosis of the intestinal microbiota (22). For example, a clinical metabolomics study 
suggested that poor utilization of tryptophan and an imbalance of tryptophan-derived 
microbiota metabolites correlated strongly with ileal crohn’s disease (ICD) (23). 
Although there is a high level of interest in identifying microbiota metabolites as well as 
characterizing molecular mechanisms for their immunomodulatory functions, there has 
been little success due to the large number of metabolites present and the complex 
network of biosysnthetic reactions carried out by the microbiota (24). 
The prevalence of obesity and related metabolic disorders has vastly increased 
throughout the world. Medical care costs of obesity in the United States are about $147 
billion in 2008 (25). Approximately, 21 million people suffer from type 2 diabetes and an 
annual total cost for treatment is over $80 billion in the United States (26). Several 
therapies such as gastric bypass and suppression of appetite have been developed for 
control of obesity but have had little success. Therefore, there is a need to develop new 
approaches against obesity. Since adipocyte differentiation and enlargement is an 
orchestrated process by the sequential induction of key transcription factors, 
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understanding an entire network between the transcription factors will provide a 
framework for manipulating obesity.  
Recently, it is demonstrated that the bacterial metabolite indole attenuates 
indicators of inflammation and improves tight junction properties in intestinal epithelial 
cells (27). This study demonstrated for the first time that microbiota metabolites are not 
simply metabolic by-products but are active molecular determinants of cellular behavior 
and responses in vivo. Moreover, development of an integrated transcription factor 
network underlying adipocyte differentiation and lipid accumulation has offered a new 
insight into understanding of obesity related disorders. Accordingly, a study for 
microbiota metabolites-triggered change in the transcription factor network is expected 
to provide a clue for treatment of obesity and metabolic disorders.  
    
1.3 RESEARCH OBJECTIVES, IMPORTANCE, AND NOVELTY  
The spectrum of metabolites present in the GI tract is extremely complex, as the 
microbiota can carry out a diverse range of biosynthetic reactions (24), including those 
that are not present in the mammalian host (28). Classical approaches such as isolating 
and culturing individual bacteria and identifying metabolites produced by them has not 
yielded much success, as many bacterial species in the GI tract cannot be cultured under 
standard laboratory conditions. Although untargeted metabolomics for profiling and 
identifying metabolites produced in the GI tract have used in recent several studies (29-
31), the untargeted approach suffers from two limitations. First, the simultaneous 
identification and quantification of a large number of metabolites remains challenging, 
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because of the variations in the dynamic ranges of different metabolites (32). Second, it 
is extremely difficult to distinguish between metabolites produced by the microbiota 
from those produced by host metabolism, as the microbiota and host share significant 
similarity in the biochemical reactions that they can carry out. Therefore, the systematic 
prediction, identification and quantification of microbiota metabolites are a significant 
and novel contribution of this work.  
To our knowledge, this is the first study to present a novel methodology which 
integrates bioinformatic prediction of microbiota metabolites with targeted 
metabolomics. The methodology predicts a panel of target metabolites that can be 
uniquely ascribed to the microbiota biochemical reactions. Targeted metabolomics 
improves dynamic range of detection and provides absolute quantitation of metabolites. 
In future, extension of the study with different in vivo models that alter gut homeostasis 
and ecology will enable us to determine the effect of perturbations on the function of the 
microbiota and its effect on host function. The identification of a mechanism for the 
immunomodulatory role of indole on immune cells (i.e., inter-domain signal recognition) 
is also a novel aspect of this study. 
 During the cellular transformation from preadipocytes into mature adipocytes, 
cells engage a network of multiple transcription factors. While many studies have 
identified roles for different transcription factors, data from these studies provide limited 
information on both expression dynamics and interaction between regulatory network 
molecules. In fact, simple inhibition of an individual regulatory molecule often has 
adverse effects; for example, the inhibition of peroxisome proliferator activated receptor-
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γ (PPARγ) in vivo reduces adipogenesis, but also increases insulin resistance, one of the 
chief complications of type 2 diabetes mellitus (33). In order to understand entire 
regulatory events underlying differentiation and enlargement of adipocytes, integration 
for dynamic interactions between transcription factors is required.  
 The integrated model of the transcription factor network underlying 3T3-L1 
adipocyte differentiation is developed by combinatorial approach of experiment and 
simulation in this study. Furthermore, the model can be applied for prediction of overall 
change of transcription factor activity profiles triggered by a specific microbiota 
metabolite and its influence on development of obesity and metabolic disorders.  
The specific objectives were to:  
 Predict metabolites that can be derived from the dietary amino acid tryptophan 
(TRP) by the microbiota, quantify the levels of the predicted TRP derivatives in 
murine cecum and feces using multiple reaction monitoring (MRM) mass 
spectrometry and demonstrate the biological activity of the metabolites at their 
physiological concentrations measuring aryl hydrocarbon receptor (AhR) 
activation  
 Elucidate the molecular mechanism underlying recognition of TRP derivatives 
in eukaryotic cells 
 Develop an integrated network model of six adipocyte transcription factors 
(PPARγ, SREBP-1c, NFAT, CREB, C/EBPβ and FoxO1) based on published 
connections between the different molecules, validate the model by measuring 
of activation dynamics during adipocyte differentiation and by perturbing the 
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activation levels of CREB to determine its effects on the other transcription 
factors 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 GUT MICROBIOTA  
 The human gastrointestinal tract (GI) contains a variety of microorganisms which 
are collectively termed gut microbiota. This community of ~10
14
 bacteria is composed of 
at least 1000 different species and dominated by anaerobic bacteria (34). Firmicutes, 
Actinobacteria and Bacteroidetes are the main bacterial phyla in human gut microbiota. 
The largest bacterial phylum, Firmicutes contains more than 200 genera, including 
Bacillus, Lactobacillus, Clostridium and Mycoplasma (35). Genomes of gut microbiota 
contain more than 100 times the number of genes as compared to our genome and are 
being increasingly described as a super organ playing important roles in immune system, 
energy balance, metabolism and host defense (36).  
 
2.1.1 GUT MICROBIOTA AND DISEASES  
Alterations of gut microbiota have been associated with several disorders and 
metabolic diseases that occur not only in the GI tract but in distant sites. Inflammatory 
Bowel Disease (IBD) is one of the most commonly reported diseases that is associated 
with dramatic changes in gut microbiota. Studies have shown that the number of 
mucosal adherent bacteria belonging to species such as Proteobacteria and 
Enterobacteriaceae is increased in patients with IBD (37). The population of 
Bifidobacterium was also found to be significantly reduced in rectal biopsies from IBD 
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patients (38). In addition, a decreased distribution of Firmicutes and butyrate producers 
such as Clostridium was noted in IBD patients (39). Roediger and co-workers 
demonstrated that overgrowth of sulphate-reducing bacteria (SRB) is associated with 
acute ulcerative colitis (40). A metabolite of SRB, hydrogen sulfide was shown to have 
genotoxic properties and produce mucosal inflammation (41).       
Obesity is the most prevalent metabolic disease worldwide and is also associated 
with reduced bacterial diversity and alterations in metabolic pathways and bacterial 
genes in the GI tract (42). Ley and co-workers found obese mice have 50% more 
Firmicutes and less Bacteroidetes as compared to lean mice (18). This was associated 
with an increase of cecal short chain fatty acids (SCFA), implying increased 
fermentation by gut microbiota and energy harvest from diet (20). Colonization of GI 
tract in germ-free mice with microbiota from conventionally raised mice showed an 
increase of insulin resistance and body fat. In addition, the colonization study found that 
the increase of body fat correlated with downregulation of fasting induced adipocyte 
factor (FIAF) in gut epithelium. Since the FIAF is a secreted lipoprotein lipase (LPL) 
inhibitor, downregulation of FIAF leads to higher LPL activity and triglyceride (TG) 
storage in adipose tissue (21). In addition, gut microbiota modulate plasma LPS level 
that triggers chronic low grade inflammation leading to diabetes (7). Non-alcoholic fatty 
liver disease (NAFLD) is another disease related to obesity. The gut microbiota 
contribute to development of NAFLD through inflammasomes that shape metabolic 
pathways of lipid accumulation (43). Inflammasome deficiency caused changes in 
configuration of gut microbiota and exacerbated hepatic steatosis and inflammation 
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through influx of Toll-like receptor 4 (TLR4) and TLR9 agonists, leading to enhanced 
tumour-necrosis factor (TNF)-α expression. 
In addition to its effect on metabolic diseases, alterations in the gut microbiota 
have a significant impact on immune responses in the host. For example, a systemic 
autoimmune disease, Rheumatoid Arthritis (RA) is associated with changes in gut 
microbiota composition and function. In serum samples of RA patients, antibodies to P. 
gingivalis were reported to be more frequent than controls and C-reactive protein 
concentration and a titer of RA-related autoantibodies were higher in individuals 
infected with P. gingivalis (44). Moreover, RA is closely related to periodontal disease. 
In subjects of RA and periodontitis, serum antibodies against disease producing 
peropdontal bacteria were more frequently detected (45).                                                                                           
Immune system development is also associated with commensal gut microbiota. 
Following birth, breastfeeding confers beneficial effects in configuration of gut 
microbiota, including increased colonization of Bifidobacteria and reduced prevalence 
of an asthma-associated pathogen, C. difficile. Antibiotics ingested by infants suppress 
colonization of commensal bacteria and cause emergence of C. difficile (46). Penders 
and co-workers found that infants colonized with C. difficile and E. coli had higher risk 
of developing recurrent wheeze and eczema (47). The presence of C. difficile and E. coli 
could be associated with a decrease of beneficial bacteria, and results in less induction of 
Treg cells by the beneficial bacteria leading to immune dysregulation.     
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2.1.2 GUT MICROBIOTA-DERIVED METABOLITES  
Conversion of proteins, carbohydrates and nonnutritive compounds by gut 
microbiota leads to formation of a variety of metabolites that have adverse or beneficial 
effects on human health. The breakdown of complex carbohydrates in the colon results 
in oligo- and monomeric compounds which are further broken down to short chain fatty 
acids (SCFA) such as butyrate and propionate (48). The formation of SCFA in the colon 
significantly impacts host responses and function. The SCFA is a significant source of 
energy, contributing 10% of daily calorie requirement for health (49). Butyrate is a main 
energy source of colonic epithelial cells and colonocytes metabolize 90% of butyrate  
(50). It functions as a main regulator of growth by promoting proliferation of epithelial 
cells and enhancing differentiation. In intracolonic milieu, the SCFA lowers pH, which 
inhibits growth of pH sensitive pathogenic bacteria and prevents degradation of primary 
bile acids to carcinogenic secondary bile acids (51). It has been proposed butyrate lowers 
risk of colon cancer by inhibiting genotoxic activity of hydrogen peroxide and 
nitrosamides in colon cells (52). It has also been reported that butyrate plays a chief role 
in chronic inflammation of intestinal mucosa. In a clinical study of Crohn’s disease, 
butyrate was shown to decrease expression of proinflammatory cytokines such as 
interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNFα) by inhibiting activation 
of nuclear factor κB (NF-κB) (53).  
 While bacterial fermentaion of carbohydrates primarily occurs in a proximal 
colon, fermentation of proteins mainly occurs in a distal colon (54). Some of products 
resulting from the amino acid fermentation are associated with diseases. For example, 
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H2S (present as HS
-
 at neutral pH) which is formed through bacterial degradation of 
cystein and methionine was shown to cause DNA hypomethylation, leading 
abnormalities of cell proliferation in crypt epithelium in ulcerative colitis (55). In 
addition, sulfate-reducing bacteria (SRB) generates sulfide from dietary sulfate by 
coupling with oxidation of lactate, succinate, ethanol and H2 (56). The anaerobic 
fermentation of aromatic amino acids by gut microbiota gives rise to several indole and 
phenol-containing compounds. Phenolic metabolites such as p-cresol were proposed to 
act as a procarcinogen in the etiology of colon cancer (57). In a rat model of depression, 
plasma concentrations of indoxylsulfate and indole-3-acetate were decreased (58). These 
altered compounds are metabolic products of amino acids by gut microbiota (59). The 
indoxylsulfate is generated by gut microbiota containing tryptophanase metabolism and 
indole-3-acetate derives from transamination on tryptophan by gut microbiota.           
Bile acids facilitate lipid absorption and participate in regulation of cholesterol, 
triglyceride and energy homeostasis, and the gut microbiota have been reported to 
modulate bile acid profiles (i.e., the spectrum of molecules produced) through 
dehydroxylation, oxidation, sulfation and deconjugation, resulting in generation of 
secondary or tertiary bile acids (60). For example, deconjugation of glycocholate by 
bacteria generates cholate, which is transformed to deoxycholate by the bacterial enzyme 
7-α-dehydoxylase. Suhre and co-workers detected that deoxycholate levels are higher in 
plasma from diabetic patients (61). Deoxycholate is the secondary bile acid and 
constitutes a major part (35%) of circulating bile acid pool in human. The secondary bile 
acids can passively enter the bile acid pool or be excreted to feces. The loss of bile acids 
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in feces is compensated by de novo biosynthesis of bile acids in the liver. Therefore, the 
higher level of deoxycholate in diabetic patients indicates alterations in the composition 
of bile acid pool and related biosynthetic pathways including conversion of primary to 
the secondary bile acids by gut microbiota. This observation is supported by the fact that 
composition of gut microbiota is between control and diabetic individuals (62).        
 
2.2 METABOLOMIC ANALYSIS OF GI TRACT  
To date, a majority of the observations on the alterations in gut microbiota in 
different disease models have been derived from high throughput sequencing studies. 
The metagenome data derived from these sequencing studies provide information only 
on alterations in the microbiota composition (i.e., population changes and/or enriched 
gene content) but do not provide information on functional changes arising from these 
alterations (63). Recent studies have used mass spectrometry (MS) methods to profile 
alterations in the metabolite levels (i.e., the products of metabolic reactions) from fecal 
material and biofluids to determine functional changes arising due to alterations in the 
metagenome. Analytical techniques such as high resolution nuclear magnetic resonance 
(NMR) spectroscopy, FTICR (Fourier transform ion cyclotron resonance)-MS, and 
chromatography have been coupled with MS enable comprehensive profiling of 
metabolites that are correlated to microbiota in the GI tract.  
Zheng and co-workers (29) applied an untargeted LC-MS (ultra performance 
liquid chromatography coupled to a tandem quadrupole-time-of-flight mass 
spectrometry) and GC-MS (gas chromatography coupled with a time-of-flight mass 
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spectrometry) to profile metabolite changes in a rodent model of antibiotic exposure. In 
this study, panels of 223 fecal and 202 urinary metabolites were significantly altered, 
showing extensive gut microbiota modulation of host metabolism involving tryptophan, 
tyrosine and short-chain fatty acid metabolism. In another untargeted MS study, 
metabolites in plasma of germ-free (GF) mice were compared to samples of 
conventional mice (64) to demonstrate that a large number of compounds in circulation 
can be attributed to the presence of microbiota in the GI tract. Specifically, phenyl 
group-containing organic acids considerably increased in presence of gut microbiota. In 
addition, the levels of indole-containing metabolites derived from tryptophan such as 
indoxylsulfate and indole-3-propionic acid (IPA) were decreased in GF mice as 
compared to conventional mice. When GF mice were injected with IPA, the high serum 
level of IPA detected after 1 h decreased more than 90% within 5 h, indicating that the 
presence of IPA in serum of conventional mice results from continuous production from 
gut microbiota. Indoxylsulfate, a known nephrotoxin that accumulates in blood of 
patients suffering from chronic kidney failure (65), is generated by transformation of a 
bacterial metabolite indole in liver. This finding illustrates bacterial metabolites can 
reach other organs and be modified by mammalian chemical processes, resulting broad 
effects on the entire body.   
Antunes and co-workers (66) used Fourier transform ion cyclotron resonance MS 
with direct infusion (DI-FT-ICR-MS) to obtain the chemical composition of the GI tract 
upon antibiotic treatment. They observed that antibiotic treatment disrupted homeostasis 
of hormone such as steroids which have been implicated in immunological responses to 
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infection and affected levels of 87% of detected 2230 metabolite features. Predictive 
mapping of altered metabolites to corresponding metabolic pathways identified various 
host metabolic functions such as steroid, bile acid, fatty acid and eicosanoid metabolism 
as being altered. Marchesi and co-workers (67) investigated fecal extracts of Crohn’s 
disease (CD) and ulcerative colitis (UC) patients by employing high resolution 
1
H NMR 
spectroscopy (68). In both fecal extracts of CD and UC patients, levels of methylamine, 
trimethylamine, acetate and butyrate were reduced, implying a change in gut microbial 
community. In a CD patient study of 15 twin pairs, individuals with ileal CD had 
increased abundance of E. coli and a lower abundance of F. prausnitzii as compared to 
healthy co-twins (69). This study also showed that increased fecal levels (i.e., poor 
utilization) of tryptophan and pnenylalanine correlated with ileal CD.  
 
2.3 AHR SIGNALING IN GI TRACT   
 The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor 
that has been shown to play a significant role in the intestinal immune system (70, 71). 
AhR is a member of the basic helix-loop-helix / Per-Arnt-Sim homology superfamily 
which plays a central role in sensing environmental factors such as light and oxygen.  
The AhR is localized in the cytoplasm and it translocates to the nucleus upon binding 
ligands such as polycyclic aromatic hydrocarbons. In the nucleus, ligand bound AhR 
forms heterodimers with the AhR nuclear translocator (Arnt) protein. The AhR-Arnt 
complex activates expression of genes containing the dioxin response element (DRE; 
GCGTG). Well known AhR target genes that are regulated by the AhR include 
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xenobiotic metabolizing enzymes such as Cyp1A1 of the cytochrome P450 family 
member (72).     
 While the AhR was identified as a part of xenobiotic metabolism, it has 
demonstrated function in immune response as well. AhR is expressed in cells involved 
in the innate immune response such as innate lymphoid cells (ILC) and in CD4
+
 T cells 
which are crucial for the adaptive immunity (70). Li and co-workers investigated AhR 
expression in a broad range of immune cells isolated from various tissues. Intraepithelial 
lymphocytes (IEL) (30) from skin and intestine demonstrated a high level of AhR 
expression. AhR deficient mice were short of IELs, which resulted in reduction of anti-
microbial peptides, an altered microbiota composition, a low level of epithelial turnover, 
and increased susceptibility for intestinal inflammation (71). Similarly, Kiss and co-
workers showed AhR deficient mice had decreased immune response and were highly 
susceptible to infection with Citrobacter rodentium (70). On the other hand, activation 
of AhR signaling inhibited colitis and inflammation in GI tract of mice (68). In addition 
to control of the immune response, it has been shown that AhR functions as a tumor 
suppressor. Fan and co-workers examined a role of AhR in the liver tumorigenesis 
induced by a genotoxic chemical diethylnitrosamine (DEN) (73). DEN-exposed Ahr
−/− 
mice exhibited elevation of tumor incidence in livers as compared to that in wild type 
littermates. They also found that expression levels of proinflammatory cytokines such as 
IL-6 and TNFα were higher in Ahr−/− mice than Ahr+/+ counterpart. Hall and co-workers 
reported that activation of AhR inhibits a metastatic process in breast cancer cell lines 
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(74). Treatment of exogenous AhR agonists inhibited motility and cell invasiveness in a 
Boyden chamber assay.        
 Ligands for AhR include various toxic halogenated aromatic hydrocarbons, 
heterocyclic amines, polycyclic aromatic hydrocarbons and a variety of indole 
containing compounds (75-77). Although many dietary compounds were initially 
suggested as natural ligands for AhR, several reports have indicated that endogeneous 
physiological ligands for AhR exist. For example, in absence of added exogenous 
ligands, expression of AhR dependent genes was induced in vitro (78, 79) and AhR 
knockout mice showed developmental defects (80). To date, many studies have 
demonstrated that a plant specific tryptophan derivative, indole-3-carbinol and its acidic 
condensation product such as indolo[3,2-b]carbazole are AhR ligands (72, 81, 82). In 
addition, endogeneous metabolites of tryptophan such as tryptamine and indole acetic 
acid were shown to bind to and activate AhR (83). Several photooxidation products of 
tryptophan were identified to bind to AhR with a high affinity and induce AhR 
dependent gene expression (84, 85). Wincent and co-workers demonstrated that 6-
formylindolo[3,2-b]carbazole (FICZ) is formed by exposure of tryptophan to visible ligh 
t and FICZ acts a substrate for CYP1A1, CYP1A2 and CYP1B1 (86). In addition, they 
found sulfo conjugates of phenolic metabolites of FICZ are present in human urine. 
These findings indicate that FICZ is naturally occurring activators of AhR signaling 
pathway.      
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2.4 TRANSCRIPTIONAL CONTROL OF ADIPOCYTE DIFFERENTIATION  
Adiposity can arise through either an increase in the number of adipocytes 
(hyperplasia) and/or an increase in the size of adipocytes (hypertrophy). Hyperplasia 
involves recruitment, proliferation and differentiation of preadipocytes while 
hypertrophy occurs due to an increase of lipid content in adipocytes (15).   
  The morphological changes and accumulation of lipid during adipogenesis are 
caused by shifts in the set of genes that are expressed at different stages of differentiation 
(17). Adipogenesis is known to follow a well characterized sequence of events that are 
regulated by the activity of different transcription factors. Initial growth arrest of 
preadipocytes is induced upon hormonal stimulation and then one or two additional 
rounds of cell division (clonal expansion) follows. During this period, there is a temporal 
increase in the expression of CCAAT/enhancer binding protein β (C/EBPβ) and C/EBPδ 
(87). It was demonstrated ectopic expression of C/EBPβ and C/EBPδ in 3T3-L1 
preadipocytes induces adipogenesis without extracellular hormones (87, 88). 
Subsequently, expression of peroxisome proliferator activated receptor- γ (PPARγ) and 
C/EBPα is stimulated (89). Several studies showed a direct link between PPARγ and 
C/EBPs. Ectopic expression of C/EBPβ and/or C/EBPδ in nonadipogenic NIH 3T3 
fibroblasts induced PPARγ, and exposure to PPARγ ligands prompted differentiation 
into adipocytes (90). Moreover, functional regulatory elements of C/EBP were identified 
in the PPARγ promoter (91). Recently, it was shown that the ectopic expression of 
C/EBPβ in fibroblasts was incapable of inducing C/EBPα without PPARγ ligands. In 
addition, retroviral expression of C/EBPβ in pparγ-/- mouse embryonic fibroblasts did not 
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stimulate expression of C/EBPα (92). On the other hand, C/EBPα-deficient embryonic 
fibroblasts did not express PPARγ and restoration of C/EBPα restored PPARγ 
expression levels (93). Therefore, the principal pathway of adipogenesis appears to 
involve 3 steps: i) expression of PPARγ induced by C/EBPβ and C/EBPδ, ii) activation 
of C/EBPα by PPARγ, and iii) positive feedback loop between PPARγ and C/EBPα.  
It is well established that PPARγ and C/EBPα function as master regulators for 
differentiation of adipocytes (94). Coexpression of PPARγ and C/EBPα could 
transdifferentiate myoblasts into adipocytes (95). Loss of function studies demonstrated 
a dominant role of PPARγ for fat cell formation and differentiation. PPARγ deficiency 
in mice caused embryonic lethality due to a placental defect. A mutant mouse that was 
rescued by using wild type tetraploid cells showed severe lipodystrophy (96). In another 
study, embryonic stem cells with homozygous deletion of PPARγ gene could not 
differentiate into adipocytes and did not participate in adipose tissue formation (97). 
Similar with PPARγ studies, C/EBPα knockout mice died soon after birth due to 
inability of glucose production, as C/EBPα is required for gluconeogenesis in liver (98). 
Ablation of the c/ebpα gene in tissues except liver showed that C/EBPα is required for 
WAT formation. In addition, deficiency of C/EBPα expression resulted in insulin 
resistance in cell culture models (93).    
Sterol regulatory element binding protein-1c (SREBP-1c) was identified as an E-
box binding transcription factor involved in adipogenesis (99). SREBP-1c promotes 
adipogenesis and activates expression of lipoprotein lipase and fatty acid synthase 
although it cannot initiate adipogenesis by itself (100). In adipose tissue, expression of 
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SREBP-1c increases in response to feeding and insulin stimulates expression of SREBP-
1c in 3T3-L1 cells (101). It was shown that SREBP-1c could activate PPARγ expression 
by binding to the PPARγ promoter (102). Dominant negative SREBP-1c expression 
inhibited adipogenesis but the inhibition could be overcome by treatment with a PPARγ 
ligand, thiazolidinedione (TZD). This result suggests a possible role of SREBP-1c in the 
production of endogenous PPARγ ligands (103).  
Cyclic AMP (43) response element binding protein (CREB) is another primary 
regulator involved in initiating adipocyte differentiation. Stimulation of CREB activity is 
induced by differentiation inducing reagents such as insulin and dexamethasone. A study 
by Zhang and co-workers provides convincing evidence that CREB is activated at a very 
early time point in adipogenesis and participates in induction of C/EBPβ expression 
(104). This result is consistent with an earlier study which mentioned a role of cAMP 
signaling for C/EBPβ expression (87). CREB exerts its function by binding to promoters 
of C/EBPβ and/or C/EBPδ and activate several adipocyte specific genes such as 
phosphoenolpyruvate carboxykinase (PEPCK) and adipocyte specific fatty acid binding 
protein (aP2). In 3T3-L1 cells, expression of dominant negative CREB blocks 
adipogenesis while expression of constitutively active CREB induces adipocyte 
differentiation (16).    
Nuclear factor of activated T cell (NFAT) is a member of the transcription factor 
family that regulates early immune response and cytokine production. It was shown that 
blocking the nuclear translocation of NFAT inhibits adipogenesis and NFAT is able to 
bind to aP2 promoter (105). NFAT has also been proposed as a regulator of PPARγ 
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activity since NFAT forms a composite enhancer complex with C/EBP and associates 
physically with PPARγ (106).    
Forkhead transcription factor FoxO1 is induced in an early stage of adipocyte 
differentiation but activation of FoxO1 is delayed until the end of clonal expansion phase. 
FoxO1 has been shown to attenuate PPARγ activation in 3T3-L1 adipocytes (107). 
Constitutively active FoxO1 prevented preadipocyte differentiation while dominant 
negative FoxO1 restored adipocyte differentiation of fibroblasts from insulin receptor 
deficient mice.  
As described above, the expression and activation of transcription factors were 
orchestrated in a temporally controlled manner to regulate adipogenesis. Based on the 
interactions between the transcription factors in the literature, Table 2.1 summarizes 
interactions between transcription factors and external stimuli that regulate their activity.  
 
2.5 INFLAMMATORY SIGNALING IN ADIPOSE TISSUE   
Obesity is characterized by chronic low-grade inflammation and progressive 
infiltration of macrophages during obesity development. In a hypertrophic state, 
adipocytes secrete TNFα, which stimulates preadipocytes to produce monocyte 
chemoattractant protein-1 (MCP-1) (108). In addition, endothelial cells within the 
adipose tissue secrete MCP-1 in response to the TNFα. The overproduction of MCP-1 
induces macrophage infiltration into the adipose tissue (109, 110). Increased secretion of 
leptin and decreased production of adiponectin in adipocytes also stimulate transport of 
macrophages to the adipose tissue and contribute to accumulation of macrophages (111).   
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Table 2.1. Interactions between the transcription factors to regulate adipogenesis 
   
Effector Target Type of interaction Reference 
CREB C/EBPβ Activation (87), (104) 
CREB C/EBPδ Activation (87) 
NFAT PPARγ Activation (106) 
FoxO1 PPARγ Repression (107) 
C/EBPβ PPARγ Activation (90), (91) 
C/EBPδ PPARγ Activation (90), (91) 
PPARγ C/EBPα Activation (92) 
C/EBPα PPARγ Activation (93) 
SREBP-1c PPARγ Activation (102) 
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Physical damage to endothelium, caused by crowding or oxidative damage due to a 
lipolytic condition may also contribute to the macrophage recruitment. Once 
macrophages are actively present, they perpetuate a cycle of macrophage recruitment, 
production of the inflammatory cytokines and impairment of adipocyte function (112).   
TNFα is one of crucial mediators in the adipose tissue inflammation. Increased 
levels of TNFα correlate with development of insulin resistance (113) whereas TNFα 
deficient obese mice remain insulin sensitive (114). Macrophage-derived TNFα which 
acts through TNFα receptors of adipocytes induces production of proinflammatory 
cytokines and lipolysis while suppressing production of anti-inflammatory cytokines in 
adipocytes. Saturated fatty acids (SFAs) are released during macrophage induced 
adipocyte lipolysis, and several studies have shown SFAs are endogeneous ligands for 
Toll-like receptor 4 (TLR4) which is necessary for recognition of lipopolysaccharide 
(LPS) (115). The TLR4 activation by SFAs induces expression of inflammatory genes 
through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
dependent mechanism (116). An in vitro coculture study with macrophages and 
adipocytes showed that SFAs upregulate expression of TNFα in macrophages through a 
mitogen-activated protein kinase (MAPK) activity (117). Adipocyte derived T helper 
cell (Th2) produced cytokines such as interleukin-4 (IL-4) and IL-13 regulate 
macrophage polarization (proinflammatory M1 state or anti-inflammatory M2 state) 
which in turn influences production of proinflammatory cytokines in adipocytes. IL-13 
treatment increased expression of PPARδ in macrophages, and adipocytes cocultured 
 24 
 
with PPARδ null macrophages produced more TNFα, MCP-1 and IL-6 as compared to 
wild type macrophages (118).  
Adiponectin which is secreted from adipocytes exerts a protective role against 
inflammation by promoting macrophage polarization toward an anti-inflammatory M2 
phenotye (119). The adiponectin expression is stimulated by PPARγ ligands such as 
thiazolidiedione (TZD) (120). In addition to PPARγ, other transcription factors such as 
SREBP-1c and C/EBPα have been demonstrated to positively regulate transcription of 
the adiponectin gene (121, 122). In human primary macrophages, PPARγ, PPARα and 
Liver X receptor (LXR) agonists were shown to increase expression of adiponectin 
receptors, implying that these transcription factors synergistically drive toward an anti-
inflammatory state (123). On the other hand, adiponectin expression is negatively 
regulated by TNFα and IL-6 (124, 125). As mentioned above, obesity-derived adipose 
tissue inflammation associates with comprehensive molecular mechanisms.  
 
2.6 NR4A REGULATION IN INFLAMMATION  
The nuclear receptor  superfamily has emerged as a therapeutic target for the 
treatment of several diseases such as atherosclerosis, diabetes and obesity (126). Studies 
on the mechanisms used by the nuclear receptor familiy to sense environmental cues and 
translate the signals into specific gene expression have expanded our understanding of 
these diseases. In addition to ligand activated transcription factors such as PPARγ, 
retinoid X receptor (RXR) and liver X receptor (LXR) (127), many orphan receptors 
whose ligands remain unknown are included in the NR superfamily. Among the orphan 
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receptors, the NR4A subgroup consists of neuron-derived clone 77 (Nur77; NR4A1), 
nuclear receptor related 1 (Nurr1; NR4A2) and neuron derived orphan receptor 1 (NOR1; 
NR4A3).  
Members of the NR4A subgroup are operated in a ligand independent manner 
(128). Structural studies have revealed that NR4A members do not possess a 
conventional ligand-binding pocket due to bulky side chains of hydrophobic amino acid 
residues (129-131). However, several small molecules have been recently described as 
agonists that may interact in unconventional ways. These molecules can work either by 
modulating C-terminal LBD (131) or N-terminal AF-1 transactivation domain (132).  
Expression of NR4A members is known to be rapidly induced by various stimuli in a 
wide range of cultured cells and tissues. Such stimuli includes agonists of G protein-
coupled receptors (133, 134), activators of protein kinase and cAMP signaling (135, 
136), UV light (137) and mechanical stress (138). Once expression is induced, NR4A 
members bind to nerve growth factor-induced protein B responsive element (NBRE; 
AAAGGTCA) as monomers (139). As homodimers or heterodimers with the other 
NR4A member, they bind to Nur-responsive element, which consists of a repeat of 
AAAT(G/A)(C/T)CA sequence . In addition, NR4A1 and NR4A2 (but not NR4A3) can 
form heterodimers with the RXR and bind to a combination of the NBRE and retinoic 
acid response elements (140).  
Recent functional studies have pointed a critical role of NR4A members in 
control of inflammation. Three NR4A receptors are induced in macrophages during 
inflammation. The expression of NR4As in macrophages depends on the activation of 
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NF-κB signaling (141). Interestingly, functional studies indicated that NR4A receptors 
both repress and activate inflammatory genes in macrophages. For example, inducible 
kinase inhibitor of nuclear factor kappa-B kinase (IKK)i/IKKε which is a NF-κB 
activating kinase was identified as a direct NR4A1 target gene and expression of NR4A1 
in macrophages potentiated inflammatory gene expression in response to LPS (142). On 
the other hand, Bonta and co-workers showed that overexpression of each NR4A 
receptor reduces expression of MCP-1, IL-6 and macrophage inflammatory protein 1α 
(MIP1α) (143). In addition, Saijo and co-workers demonstrated that NR4A2 represses 
transcription of TNFα and IL-1β in macrophages and microglia. This transrepression is 
mediated by recruitment of corepressor for element-1 silencing transcription factor 
(CoREST) complex to a target promoter and clearance of NF-κB (144).  
Several natural and synthetic compounds have been recently identified as 
agonists for NR4A receptors, but endogenous ligands have not been identified. The first 
agonist 6-mercaptopurine was identified through high throughput screening for all 
NR4A members and some related thiopurine compounds were demonstrated to activate 
NR4A3. Activation of NR4A2 and NR4A3 by 6-mercaptopurine was independent of the 
ligand-binding domain (LBD) and involved modulation of activation function-1 (AF-1) 
within the amino-terminal regulatory domain (129, 145, 146). Several compounds based 
on 1,1-bis(3’-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs) have been identified 
as agonists of NR4A1. In deletion studies, C-DIM activity was dependent on the LBD of 
NR4A1. The C-DIMs have been demonstrated to induce proapoptoic pathways in cancer 
cells, supporting a proapoptoic function of NR4A1 (132, 147). A series of compounds 
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based on a benzimidazole scaffold were discovered by in silico screening methods. 
These compounds were shown to be potent agonists of NR4A2 in vitro (148). Zhan and 
co-workers identified cytosporone B from Dothiorella sp. HTF3 as an agonist of NR4A1, 
which binds to the LBD and induces apoptosis in cancer cells in vitro (149). Thus, 
manipulation and exploitation of NR4A by these small molecule agonists from the 
preliminary studies may provide therapeutic modalities against inflammatory diseases.       
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CHAPTER III 
PREDICTION, IDENTIFICATION, AND QUANTIFICATION OF 
MICROBIOTA METABOLITES IN MURINE GUT USING IN SILICO 
TARGETED METABOLOMICS 
 
3.1 INTRODUCTION 
The human gastrointestinal (GI) tract is colonized by ~10
14
 bacteria belonging to 
~1,000 species that are collectively termed the microbiota. Disruptions in the microbiota 
composition (dysbiosis) are increasingly correlated to not only gut diseases such as 
inflammatory bowel disease (IBD) and colitis (4), but also obesity, insulin resistance and 
type 2 diabetes (6, 42). There is increasing evidence that the functional outputs of the 
microbiota, specifically the metabolites they produce, are important modulators of host 
physiology. For example, recent work from our laboratory demonstrated that the 
tryptophan (TRP)-derived bacterial metabolite indole attenuates indicators of 
inflammation and improves tight junction properties in intestinal epithelial cells (27). An 
increase in the conversion of dietary choline into trimethylamine by the gut microbiota 
has also been correlated to non-alcoholic fatty liver disease (11) and cardiovascular 
diseases (12). 
Despite a high level of interest, only a handful of bioactive microbiota 
metabolites in the GI tract have been identified. One major challenge is that the spectrum 
of metabolites present in the GI tract is extremely complex, as the microbiota can carry 
out a diverse range of biotransformation reactions, including those that are not present in 
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the mammalian host (28). Classical approaches such as isolating and culturing individual 
bacteria and identifying metabolites produced in these cultures has not yielded much 
success, as many bacterial species in the GI tract cannot be cultured under standard 
laboratory conditions. Moreover, this approach also does not account for community-
level interactions between the bacteria as metabolites produced by one bacterial species 
can be utilized or modified by other species resident in the local microenvironment. 
Another challenge is that it is also extremely difficult to determine whether a metabolite 
is the product of microbiota or host metabolism, as most metabolite classes are present in 
both bacteria and mammals due to the high degree of conservation of metabolic 
pathways across organisms. 
In addressing these challenges, metabolomics of fecal or bodily fluid samples has 
emerged as an attractive approach to explore the metabolite profiles of the GI tract, and 
to compare these profiles under different conditions. Mass spectrometry (MS)-based 
approaches have been especially useful in high-throughput identification of a broad 
spectrum of metabolites. For example, a recent study by Zheng and co-workers (29) used 
chromatographic separation coupled with MS to characterize the impact of antibiotic 
treatment on the metabolome of rat fecal and urine samples, and observed that the levels 
of more than 200 metabolites were significantly altered. Interestingly, TRP-derived 
compounds such as indole and tryptamine were among the significantly altered 
metabolites in both fecal and urine samples. In a related study, Antunes and co-workers 
(66) used Fourier transform ion cyclotron resonance MS to detect more than 2,000 
metabolite features in murine fecal samples, and found that a single high dose of 
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streptomycin causes significant changes in 88% of these features. In addition to MS, 
highresolution NMR spectroscopy has also been used to broadly profile the metabolites 
whose levels in feces, bodily fluids or host tissues are significantly altered by 
interventions (such as bariatric surgery) that are expected to perturb the gut microbiota 
(150). In general, MS offers greater sensitivity compared to NMR, and has become the 
dominant analytical platform for metabolomics (151).  
To date, a majority of MS studies on profiling GI tract metabolites have utilized 
an untargeted approach to achieve high throughput. While this approach offers the 
benefit of potential for discovery, it also has several drawbacks. Due to the complexity 
of the mass spectra obtained, especially when full scan tandem mass spectrometry 
(MS/MS) is employed, metabolite identification can be difficult, as it is difficult to 
discriminate between ions and ion fragments having the same mass-to-charge ratio (m/z). 
High-resolution time-of-flight (TOF) mass spectrometers can somewhat alleviate this 
problem (151). However, quantification remains a challenge, because the dynamic range 
of different metabolites in a biological sample can span up to nine orders of magnitude 
(32), and an untargeted approach precludes tailoring of MS parameters for ionization and 
fragmentation of specific, low-abundance metabolites. In contrast, targeted approaches, 
where the analytes are determined a priori, can use quantitative methods such as multiple 
reaction monitoring (MRM) that afford custom optimization of MS parameters for 
individual metabolites to enable sensitive detection. On the other hand, a targeted 
approach is limited in its discovery potential, as only a focused set of metabolites is 
analyzed simultaneously. Expanding the number of MRM transitions, and thus detecting 
 31 
 
more analytes in a single run, requires a reduction in the dwell time to preserve peak 
shape, which can compromise sensitivity (151). 
In this work, we present a novel targeted metabolomics methodology that 
addresses the inherent discovery limitation by integrating an in silico prediction step into 
the MS workflow to identify bioactive microbiota metabolites. To date, bioinformatics 
tools have been utilized in metabolomics generally for post-hoc analysis to process raw 
data (152), or perform statistical comparisons (153). Recently, Greenblum and co-
workers presented an elegant metagenomic study that places obesity or IBD-associated 
variations in human gut microbiota gene abundances in the context of a microbial 
community-level metabolic network reconstructed in silico (154). Here, we similarly 
model microbiota metabolism using a metabolic network representing a single 
“microbial metabolic organ” to computationally explore the products of microbiota 
metabolism. We thus exploit efficient computational algorithms for network analysis and 
the growing catalogue of annotated microbial genomes to conduct in silico discovery 
experiments. As a result, the analytical effort can focus on a relatively small number of 
metabolites to support facile quantitation. To validate our methodology, we use 
computational pathway analysis to predict bacterial products of tryptophan (TRP) 
metabolism, and utilize MRM coupled with liquid chromatography (LC) to quantify the 
levels of the predicted metabolites in murine cecum and feces. To determine bioactivity 
of the metabolites, we use a Gaussia luciferase (Gluc) reporter system measuring aryl 
hydrocarbon receptor (AhR) activation. Our results have the potential to facilitate 
mechanistic studies on host-bacteria interactions in the intestinal tract.  
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3.2 MATERIALS AND METHODS 
 
3.2.1 MATERIALS 
 All chemicals including HPLC-grade solvents and high-purity metabolite 
standards were purchased from Sigma-Aldrich (St. Louis, MO) unless noted otherwise.  
 
3.2.2 PREDICTION OF MICROBIOTA METABOLITES 
 We used a probabilistic pathway construction algorithm to predict possible 
metabolites that can derived from a given source metabolite through the metabolic 
reactions of the gut microbiota. Previously, the algorithm was used to explore novel 
synthesis pathways for both native and nonnative metabolites in a particular microbial 
host (Escherichia coli) (155). In this study, the algorithm was modified to construct 
bacterial biotransformation pathways that are nonnative to the mammalian host organism, 
i.e. mouse, such that the intermediates of the constructed pathways could be 
unambiguously sourced to bacterial metabolism. A list of metabolic reactions for the 
mouse was compiled from published genome-scale models (156, 157) and manually 
crossreferenced with the KEGG database to identify the corresponding reaction and 
compound identification numbers. The algorithm recursively constructs a tree, starting 
from a source metabolite as a root of the tree. A single reaction is randomly selected 
from a list of candidate bacterial reactions in the KEGG enzyme database that involve 
the source metabolite as a main reactant. This list, obtained through KEGG’s FTP site, 
comprised all bacterial enzymes catalogued in the database as specified by the genes 
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entry. An enzyme was determined to be bacterial if at least one bacterial species encoded 
the enzyme in its genome. The selected reaction is then added to the tree and represented 
by an edge. This edge expands the tree by attaching new nodes representing the product 
metabolites and cofactors of the selected reaction. The construction thus proceeds in a 
depth-first fashion. Each of these nodes is a new root for the recursion, unless the 
corresponding metabolite or cofactor is already present in the host organism or was 
previously added to the tree. To achieve reasonable runtimes (on the order of tens of 
minutes for a run of 1,000 – 2,000 iterations), the size of the search space was 
constrained by placing an upper limit on the number of reactions that can be used to 
construct a pathway. In this study, the upper limit was varied from 20 to 50, which had 
no observable impact on the distribution of the predicted metabolites. When the addition 
of a reaction to the tree violates the upper limit, the algorithm backtracks and proceeds 
by adding to the tree another reaction that has not been previously explored, effectively 
identifying an alternative pathway. If none of these alternative routes satisfy the pathway 
length limit, the algorithm further backtracks and continues from there. The algorithm 
finishes when all permitted-length branches of the tree terminate in a metabolite that is 
native to the host organism. Due to the probabilistic nature of selecting the reactions, the 
completed tree does not exhaustively enumerate all possible pathways. Rather, each tree 
represents a single pathway from the source metabolite to one or more product 
metabolites that are native to the host organism. Therefore, the search is iterated many 
times to explore a diverse number of possible pathways. In our previous work, we found 
that the probabilistic search matches an exhaustive search in terms of sampling diversity, 
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and dramatically outperforms the exhaustive search in terms of computational efficiency 
(155).  
 
3.2.3 SAMPLE COLLECTION 
Female C57BL/6 mice at 5 weeks and 14 weeks of ages were purchased from 
Jackson Laboratories (Bar Harbor, Maine) and allowed to orient to colony for 1 week. 
All mice were maintained in a pathogen free animal facility located at Texas A&M 
Health Science Center. The animals were handled in accordance with the Institutional 
Animal Care and Use Committee guidelines under an approved animal use protocol. The 
young and old mice (n = 7) were sacrificed at 6 and 15 weeks of age, respectively. The 
entire cecum (tissue with luminal contents) and fecal pellets were collected from each 
animal. The samples were weighed, flash frozen, and stored at -80oC before processing 
for extraction.  
 
3.2.4 METABOLITE EXTRACTION 
Metabolites were extracted from cecum or fecal pellets luminal contents and 
fecal samples using a solvent-based method (158) with minor modifications. Briefly, 1.5 
ml of ice-cold methanol/chloroform (2:1, v/v) was added to a sample tube containing a 
pre-weighed luminal content or fecal sample. After homogenization on ice, the sample 
tube was centrifuged under refrigeration (4 
o
C) at 15,000 × g for 10 min. The supernatant 
was then transferred to a new sample tube through a (70-μm) cell strainer. After adding 
0.6 mL of ice-cold water, the sample tube was vortexed vigorously and centrifuged 
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under refrigeration (4 
o
C) at 15,000 × g for 5 min to obtain phase separation. The upper 
and lower phases were separately collected into fresh sample tubes with a syringe, taking 
care not to disturb the interface. To improve signal intensity for MS, 500 μL of the polar 
phase was concentrated by solvent evaporation in a Savant speedvac concentrator 
(Thermo Scientific, Asheville, NC), and then reconstituted in 50 μL of methanol/water 
(1:1, v/v). Extracted metabolites were stored at -80
o
C until analysis.  
 
3.2.5 METABOLITE ANALYSIS 
Prior to sample analysis, MS parameters were optimized for each target 
metabolite to identify the MRM transition (precursor/product fragment ion pair) with the 
highest intensity under direction injection at 10 μL/min. The following parameters were 
optimized operating in positive mode: declustering potential (DP), entrance potential 
(EP), collision energy (CE), and collision cell exit potential (CXP). The optimized 
parameter values for the target metabolites analyzed in this study are shown in Table 3.1. 
The target metabolites in samples were detected and quantified on a triple quadrupole 
linear ion trap mass spectrometer (3200 QTRAP, AB SCIEX, Foster City, CA) coupled 
to a binary pump HPLC (1200 Series, Agilent, Santa Clara, CA). Peak identification and 
integration were performed using Analyst software (version 5, Agilent, Foster City, CA). 
Samples were maintained at 4
o
C on an autosampler prior to injection. Chromatographic 
separation was achieved on a hydrophilic interaction column (Luna 5 μm NH2 100 Å  250 
mm × 2 mm, Phenomenex, Torrance, CA) using a solvent gradient method (159).  
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Table 3.1. Optimized MRM-MS parameters for detection of TRP metabolites 
 
Compound Precursor (Da) Product (Da) DP (V) EP (V) CE (V) CXP (V) 
Indole 118.0 91.0 41.0 10.0 27.0 2.5 
Indole 3-acetate 176.0 130.0 31.0 9.0 19.0 4.0 
Indole 3-acetamide 175.0 130.0 26.0 10.0 19.0 4.0 
Tryptamine 161.0 144.2 11.0 4.0 15.0 4.0 
Hydroxyindole 134.1 77.1 26.0 10.0 37.0 2.5 
Tryptophan 205.0 188.0 21.0 10.0 17.0 4.0 
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Solvent A was an ammonium acetate (20 mM) solution in water with 5 % acetonitrile 
(v/v). The pH of solvent A was adjusted to 9.5 immediately prior to analysis using 
ammonium hydroxide. Solvent B was pure acetonitrile. Injection volume was 10 μL. 
The gradient method, including solvent flow rate and composition, is shown in Table 3.2.  
 
3.2.6 PARTITION OF METABOLITES IN EXTRACTION SOLVENT  
 Since only the upper (polar) phase of the biphasic metabolite extract was used for 
analysis, the partition of all five metabolites between the two phases was determined for 
absolute quantification. Briefly, 5 μL of the metabolite’s stock solution (1 mg/mL) was 
dispensed into a 1.5 mL microfuge tube. To this pure stock solution, 750 μL of 2:1 
methanol:chloroform was added, followed by 300 μL of water. Following centrifugation 
and phase separation, the upper phase was collected and analyzed for the target 
metabolite using the corresponding optimized MRM parameters. The difference between 
measured and theoretical amounts of the metabolite was used to determine the partition 
between phases. For example, the theoretical amount of tryptophan in the stock solution-
solvent mixture is 25 nmol. The measured concentration in the upper phase was 34 μM, 
which corresponds to an estimated total amount of ~27 nmol in the upper phase (volume 
800 μL), suggesting that all of the tryptophan is recovered within a margin of (e.g. 
pipetting) error. Similarly, all other metabolites analyzed in this study showed full 
partition into the upper phase, except indole. For indole, of the 42 nmol dispensed, only   
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Table 3.2. Solvent gradient method for metabolite separation 
  
Time (min) 
Flow rate 
(µL/min) 
A (%) B (%) 
0 300 15 85 
15 300 100 0 
28 300 100 0 
30 300 15 85 
50 300 15 85 
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17 nmol was recovered in the upper phase, indicating that the actual amount of indole 
extracted from the tissue is ~2.5 times greater than the measured amount.  
 
3.2.7 STATISTICAL ANALYSIS 
 Comparisons of medians between the metabolite levels of young and old mice 
were performed with the non-parametric two-sided Mann-Whitney U-test. The null 
hypothesis that the two medians are the same was rejected for p < 0.05. Comparisons of 
means for the reporter experiments were performed using the Student’s t-test. The null 
hypothesis that the two means are the same was rejected for p < 0.05. 
 
3.2.8 CELL CULTURE 
 A MCF-7 human breast cancer cell line was obtained from ATCC (Manassas, 
VA). MCF-7 cells were cultured at 37 °C with 5 % CO2 in RPMI 1640 medium (MP 
Biomedicals, Solon, OH) supplemented with 10% (v/v) fetal bovine serum (FBS), 
glucose (2.5 g/L), HEPES (10 mM), sodium pyruvate (1 mM), sodium bicarbonate (2 
g/L), penicillin (100 U/ml) and streptomycin (100 μg/ml). A stably transfected rat 
hepatoma (H4IIE) cell line containing an AhR-responsive enhanced green fluorescent 
protein (EGFP) reporter was kindly provided by Prof. Michael Denison (University of 
California, Davis, CA) (160). The H4IIE cells were cultured at 37 °C with 5 % CO2 in 
alpha minimum essential medium (Mediatech, Manassas, VA) supplemented with 10 % 
(v/v) FBS, glucose (3.5 g/L), sodium bicarbonate (2.2 g/L), penicillin (100 U/ml) and 
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streptomycin (100 μg/ml). Serum-free medium was used for assays on AhR activity in 
the H4IIE reporter cells.  
 
3.2.9 CONSTRUCTION OF GAUSSIA LUCIFERASE REPORTER PLASMID 
 A lentiviral reporter plasmid for monitoring activation of AhR was constructed as 
described below. AhR response elements (RE) in target promoter were identified using 
the TRANSFAC database 7.0 Public. An oligonucleotide containing three repeats of the 
binding sequence (CTGAGGCTAGCGTGCGT) separated by 4 - 6 bases (spacer 
sequence) was chemically synthesized with two restriction enzyme (EcoRI and AfeI) 
cleavage sites at the ends. The RE oligonucleotide was cloned into a lentiviral vector 
(161) in which expression of the Gaussia luciferase (Gluc) is under the control of a 
minimal CMV promoter and red fluorescent protein (RFP) is constitutively expressed. 
Expression of Gluc is induced when ligand-activated AhR binds to its RE. Clones 
containing the correct RE were identified by multiple restriction enzyme digests and 
verified by sequencing.  
 
3.2.10 GENERATION OF A STABLE MCF-7 REPORTER CELL LINE 
 A stable MCF-7 AhR reporter cell line was generated by lentiviral transduction. 
To produce lentiviral particles, AhR reporter plasmid and helper plasmids psPAX 
(plasmid 12260, Addgene, MA) and pMD2.G (plasmid 12259, Addgene) were co-
transfected into 293T/17 cells using the calcium phosphate transfection method (162). 
After 24 h following the transfection, the medium was replenished and 5 mM of sodium 
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butyrate was added. After an additional 24 h of incubation, culture supernatants 
containing viral particles were collected, pooled, filtered with 0.45 μm filters, and 
centrifuged for 2 h at 4°C at 48000 x g. The viral titer was measured using a Lenti-X 
qRT-PCR titration kit (Clontech, Palo Alto, CA). To transduce MCF-7 cells, a 
concentrated aliquot of virus particles (~1 x 10
8 
IFU) was added to the cells in presence 
of Polybrene (hexadimethrine bromide). After 4 h of incubation with the virus particles, 
the medium was replenished. 
 
3.2.11 AHR ACTIVATION STUDIES 
 The MCF-7 and H4IIE reporter cells were seeded in 24-well tissue culture plates 
and grown to 70% confluence. Cells were treated with indicated concentrations of target 
metabolites (i.e., indole, tryptamine, indole-3-acetate, indole-3-pyruvate and indole-3-
acetamide). The negative and positive controls were 0.1% (v/v) N, N-
dimethylformamide (DMF) and 20 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
respectively. For assays using the MCF-7 reporter cells, 20 μL of culture supernatant 
was collected at 24 h and 48 h post-treatment. The MCF-7 supernatant samples were 
stored at -20 °C until the secreted luciferase activity was measured. The luciferase 
activity (relative light units; RLU) was used to calculate the rate of Gluc production 
(RLU divided by the time over which Gluc was secreted). To account for differences in 
cell density between different experiments, the Gluc production rate was normalized by 
the intensity (relative fluorescence units; RFU) of the constitutively expressed RFP 
measured at 550/600 nm excitation/emission. The AhR activity reported by H4IIE cells 
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was quantified using fluorescence optical microscopy based on the green fluorescence 
intensity of EGFP. 
 
3.3 RESULTS 
 
3.3.1 TRYPTOPHAN DERIVATIVES 
 Starting with tryptophan as the source metabolite, biochemical transformation 
pathways were computationally constructed from candidate bacterial reactions 
catalogued in the KEGG database (163). As the goal was to predict metabolic 
derivatives that could be formed by the gut microbiota, but not the murine host, pathway 
construction was terminated when a metabolite was encountered that could also be 
formed through host (murine) metabolism. Due to the probabilistic nature of the pathway 
construction algorithm, the results can vary with the number of iterations. Therefore, we 
performed a series of simulations with varying iteration numbers, and examined the 
diversity of predicted metabolic derivatives. No further increase in the number of unique 
metabolic derivatives was observed beyond iteration number 1,500 (Fig. 3.1A). 
Moreover, the ordering of the metabolic derivatives in terms of their relative selection 
frequency also remained constant. Holding the iteration number constant at 1,500, we 
next performed 50 separate runs of the pathway construction algorithm to calculate 
average frequencies for the selected metabolic derivatives (Fig. 3.1B). Of the 26 
predicted metabolic derivatives, 12 derivatives with the highest selection frequency 
accounted for > 90% of all metabolite selections as pathway intermediates. Interestingly,  
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Fig. 3.1. Probabilistic pathway construction with a tryptophan source. (A) Number of 
unique metabolites selected using probabilistic pathway construction with TRP as the 
source metabolite. (B) Average selection frequencies of TRP pathway metabolites at 
iteration number 1,500 (50 repeated runs). (C) Correlation of metabolite selection 
frequency and distance from the source metabolite. In (B) and (C), error bars indicate 
standard deviations.  
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a significant correlation between selection frequency and reaction distance (number of 
enzymatic steps) from the source metabolite TRP was not observed for these 12 most 
frequently selected metabolites. However, there was a significant negative correlation 
between selection frequency and reaction distance when all 26 metabolites were 
included in the analysis (Fig. 3.1C). The metabolite farthest away from the source 
metabolite was acetyl-phosphate, with an average reaction distance of 10.5, which is 
well below the pathway length limit of 50 we set for the algorithm. 
 Representative tryptophan biotransformation routes and intermediates predicted 
by the pathway construction algorithm are shown in Fig. 3.2. To explore potential 
biotransformation of TRP products that could be present in the intestinal mucosa, we 
also analyzed the metabolic derivatives of two neighboring metabolites, tryptamine and 
indole, both of which can be formed from TRP in a single enzymatic step. Tryptamine 
can be formed via an aromatic-L-amino-acid decarboxylase (EC 4.1.1.28), which is 
encoded by the dopa decarboxylase gene (ddc) in the mouse (164), although the 
expression of this enzyme has not been reported in intestinal tissue. Indole can be 
formed via tryptophanase (tnaA), which is expressed in a number of species of the 
murine gut microbiome. For tryptamine, the number of unique derivatives identified by 
our algorithm was 54 at an iteration number of 1,500. Similar to tryptophan, the 
selection frequencies were highly uneven, with 10 metabolites accounting for >95% of 
all metabolite selections. Every one of these 10 metabolites was also predicted as TRP 
derivatives. For indole, the maximal number of unique derivatives identified by our 
algorithm was only three: 1-(2-carboxyphenylamino)-1-deoxy-D- ribulose 5-phosphate,  
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Fig. 3.2. Representative tryptophan biotransformation routes and intermediates predicted 
by the pathway construction algorithm. Metabolites quantified in this study using MRM 
MS are indicated in bold. Arrows representing enzymatic reactions are labeled by the 
corresponding enzyme commission number (EC#). Some reactions (e.g. conversion of 
tryptophan into indolepyruvate) can be catalyzed by multiple enzymes. Similarly, some 
metabolic derivatives (e.g. indole-3-acetaldehyde) can be produced through multiple 
routes. 
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indoleglycerol phosphate, and N-(5-phospho-D-ribosyl)anthranilate. The iteration 
number needed to obtain a stable set of relative selection frequencies for the predicted 
derivatives was also lower than TRP or tryptamine (only 200), presumably due to the 
lower connectivity of reactions involving indole. Similar to the high-frequency 
tryptamine derivatives, every indole derivative was a subset of the predicted TRP 
derivatives. 
 
3.3.2 QUANTIFICATION OF METABOLITES USING MULTIPLE REACTION 
MONITORING (MRM) 
 Of the 12 high-frequency metabolites predicted by the pathway algorithm to be 
derived from TRP by bacteria, a subset was selected for MRM analysis based on 
availability of pure standards and ease of ionization and fragmentation. For example, 
indole 3-acetaldehyde was excluded, because a high-purity was not available to generate 
a standard curve. Indole 3-pyruvate was excluded, because it ionized poorly, and thus 
had a high limit of detection (LOD) in comparison with the other metabolites targeted 
for analysis. The final panel of metabolites targeted for analysis comprised indole, 
hydroxyindole, indole 3-acetate, indole 3-acetamide, tryptamine and TRP. 
Hydroxyindole was added to the panel based on recent reports suggesting that it is 
derived from indole through bacterial reactions (20). All six metabolites were 
simultaneously identified and quantified in murine fecal and cecum extracts using MRM 
MS following separation by hydrophilic interaction chromatography (HILIC). 
Metabolite identification was performed based on both chromatographic retention time 
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and mass signatures, as we found that even an optimized MRM transition (precursor-
product ion pair) did not always uniquely identify a metabolite in a complex biological 
sample. For indole, the optimal ion pair transition based on MS signal intensity was 
118/91 m/z. The elution time of this transition ranged from 2.2 and 2.9 min for standards 
containing the corresponding high-purity chemical (Fig. 3.3A). The linear response of 
signal area under curve (AUC) with respect to concentration is shown for concentrations 
up to 85 μM (Fig. 3.3A; R2 = 0.998, p < 10-4), with an estimated LOD (defined as the 
peak height of 10-times the baseline signal) of 4.6 μM. For tissue extracts, we observed 
multiple peaks corresponding to the signal-optimized indole transition, highlighting the 
importance of matching the retention time to unambiguously identify a metabolite (Fig. 
3.3B, Fig. 3.4 for chromatograms of all metabolites). To determine whether the MRM 
method could be used to detect physiological differences in metabolite levels, we 
compared the fecal pellet and cecum concentrations of TRP and its derivatives in young 
(age 6 weeks) and old (age 15 weeks) female C56BL/6 mice fed standard chow (Fig. 
3.5). All six metabolites were detected in both fecal pellet and cecum extracts from 
young and old mice. For cecum extracts, statistically significant differences (p < 0.05) 
were found between young and old mice for all metabolites except tryptamine. For fecal 
extracts, statistically significant differences were found only for indole 3-acetate. Unlike 
the fecal extracts, metabolite levels in the cecum extracts could be meaningfully 
expressed as tissue concentrations by normalizing the absolute molar quantities with 
respect to the weight of the source tissues and approximating tissue density with that of   
 48 
 
 
 
Fig. 3.3. LC-MS/MS chromatogram for indole. (A) indole standard (107 ng/L). Peaks 
correspond to 118 > 91 (m/z) MRM transition. Retention time of indole lies between 
2.2 and 2.9 minutes. Signal Area Under Curve (AUC) is also plotted as a function of 
indole concentration (R
2
 =0.998, p < 10
-4
). (B) Representative sample with peaks 
corresponding to the 118 → 91 (m/z) MRM transition. Sample shown was extracted 
from the cecum of a young mouse (6 weeks of age).  
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Fig. 3.4. LC-MS/MS chromatogram for all target metabolites. (A) Indole 3-Acetate, 
MRM: 176>130 (B) Indole 3-Acetamide, MRM: 175>130 (C) Hydroxyindole MRM: 
134.1>77.1 (D) Tryptophan MRM: 205>188 (E) Tryptamine, MRM: 161>144.2, 
standards (left) and metabolite extracts of week 5 cecum samples (right).  
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Fig. 3.5. Comparison of metabolite concentrations between young (6 weeks of age) 
and old (15 weeks of age) mice. Metabolite concentrations were normalized to the 
corresponding mass of fecal pellet. (A) cecum extracts (B) fecal extracts. 
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water (1 g/ml). For example, after accounting for the partition of indole between the 
polar and nonpolar phases of the metabolite extraction solvent, the normalized tissue 
concentrations for indole ranged from 9.7 to 40 μM These are conservative estimates, as 
it is expected that the efficiency for the extraction of metabolites from tissue into solvent 
is less than 100 %.  
 
3.3.3 ACTIVATION OF AHR BY MICROBIOTA METABOLITES 
 We investigated if the identified microbiota metabolites could be putative ligands 
in host cells and activate eukaryotic signaling pathways. Specifically, we investigated 
the ability of identified microbiota metabolites to act as agonists for the AhR, as 
previous studies (83) have shown that endogenous TRP-derived metabolites can activate 
AhR signaling. MCF-7 cells with a stably integrated Gaussia luciferase (Gluc) reporter 
plasmid for AhR binding activity were incubated with 100 μM microbiota metabolites or 
20 nM TCDD (positive control) for 48 h, and luciferase activity in culture supernatants 
was measured. Exposure to TCDD, a high-affinity AhR agonist, resulted in a 2-fold 
increase in the rate of AhR-driven luciferase activity (RLU/h/RFU) as compared to the 
solvent control (Fig. 3.6). Exposure to indole-3-acetate, tryptamine and indole-3-
pyruvate also resulted in similar induction of AhR activity. Indole-3-acetamide resulted 
in a 1.3-fold statistically significant (p < 0.02) increase in AhR binding activity at 24 h 
but not at 48 h. Interestingly, indole did not induce activation of AhR, suggesting that 
the core indole moiety is by itself not sufficient to elicit a significant response. Similar 
results were also observed in the H4IIE rat liver reporter cell line using GFP as the     
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Fig. 3.6. AhR activation by TRP-derived metabolites. Activity assays were 
performed at a dose of 100 μM for each metabolite. AhR activity is reported as the 
rate of luciferase activity normalized to red fluorescence of constitutively expressed 
RFP (RLU/h/RFU). Positive and negative controls were 20 nM TCDD and 0.1% 
(v/v) DMF, respectively. 
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  Fig. 3.7. Microbiota metabolites screen for AhR activation in the H4IIE reporter cells. 
The H4IIE cells containing an AhR-responsive enhanced green fluorescent protein 
(EGFP) reporter were seeded in 24-well tissue culture plates and cultured to 70% 
confluence. Cells were treated with 100 μM of target metabolites or 0.1 % (v/v) of 
DMF. Green fluorescent images were taken at 48h post-treatment. (A) DMF, (B) 
indole, (C) indole-3-acetate, (D) tryptamine, (E) indole-3-pyruvate, (F) indole-3-
acetamide 
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readout (Fig. 3.7). For metabolites that induced AhR binding activity at 100 μM, we 
performed dose response experiments to determine concentration effects on induction of 
AhR activity. Exposing MCF-7 reporter cells to increasing concentrations of indole-3-
acetate and tryptamine resulted in a dose-dependent increase in AhR activity (Fig. 3.8). 
Exposure to indole 3-pyruvate, one of the in silico predicted metabolites, but not 
quantified due to poor ionization, also showed a dose dependent increase (Fig. 3.9). The 
dose-dependent increase in AhR-dependent reporter activity was also confirmed using 
H4IIE reporter cells (Fig. 3.10). 
 
3.4 DISCUSSION  
 In this study, we present a methodology for the prediction, identification and 
quantification of gut microbiota metabolites that integrates computational pathway 
analysis into a targeted metabolomics workflow. The effects of physiological or 
pathological perturbations on the microbiota have been investigated using metagenomic 
analyses characterizing the composition of the gut microbial community, the enrichment 
(or depletion) of bacterial genes, or the expression levels of genes for specific metabolic 
pathways (20, 165, 166). A limitation of these analyses is that they do not provide direct 
information on the products of bacterial metabolism such as which molecules are formed 
from bacterial biotransformation reactions and the concentrations at which these 
metabolic products are present. Thus, the ability to unambiguously identify bacterial 
metabolites and quantify their levels in the GI tract is expected to have a significant 
impact on the study of human gut microbiome function.   
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Fig. 3.8. Dose dependent activation of AhR upon exposure to indole-3-acetate and 
tryptamine. Data shown are mean ± standard deviation from four replicate 
experiments. Asterisk (*) indicates statistical significance at p < 0.05. 
   
 56 
 
 
 
  Fig. 3.9. Dose dependent activation of AhR upon exposure to indole 3-pyruvate. 
Data shown are mean ± standard deviation from four replicate experiments. Asterisk 
(*) indicates statistical significance at p < 0.05.  
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Fig. 3.10. Dose-dependent AhR activation in the H4IIE reporter cells. (A) 
Tryptamine, (B) Indole 3-Acetate, and (C) Indole 3-Pyruvate. The H4IIE cells 
containing an AhR-responsive enhanced green fluorescent protein (EGFP) reporter 
were seeded in 24-well tissue culture plates and cultured to 70% confluence. Cells 
were treated with indicated concentrations of target metabolites. Green fluorescent 
images were taken at 48h post-treatment. 
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 One limitation of the in silico metabolite prediction step is that its reliability is 
predicated on the accuracy and completeness of the KEGG pathway database. While the 
KEGG database is continually and frequently updated, it is certainly possible that our 
predictions lag behind newly published discoveries regarding microbiota metabolism. 
For example, Wikoff and coworkers recently identified indole 3-propionate as a TRP-
derived metabolite that is produced by the gut microbiota (64). However, at the time of 
completion of this work, this metabolite was not listed in the KEGG compound database, 
and thus could not be identified by our algorithm. Similarly, the discrimination of 
bacterial metabolites from metabolites that could also be produced by host cells depends 
on an accurate model of host metabolism. The most relevant host genomes, e.g., mouse 
and human, have been sequenced and largely annotated, and several published models 
are available that exhaustively catalogue the metabolic reactions. However, prior studies 
with genome-scale model reconstruction suggest that several iterations may be required 
until the published models can be considered stable, consensus reconstructions (167).  
 Another limitation of the prediction algorithm is that it does not differentiate 
between reactions based on their gene abundance or expression level when constructing 
a possible biotransformation route. Consequently, each candidate reaction that can be 
connected to the source metabolite has an equal likelihood of selection, which unlikely 
reflects the true engagements of metabolic reactions in the gut microbiota. In principle, 
metabolites produced by reactions encoded by genes that are highly abundant and/or 
highly expressed should more likely be present at quantifiable levels compared to the 
products of depleted or minimally expressed pathways. In this regard, both of the present 
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limitations of the in silico prediction step could be addressed by incorporating 
metagenomic data on as they become available. Our pathway construction already 
accepts user-specified selection weights, and could be extended in a straightforward 
manner to explore a microbiota metabolic network weighted by relative gene 
abundances or expression levels. 
 A key advantage of MRM as a MS technique for targeted metabolomics is that 
the detection of precursor-product ion pairs offers greater specificity compared to full 
scan MS, while allowing absolute quantitation. This targeted approach also allows for 
enhanced sensitivity as well as improved LOD, because instrument-specific parameters 
can be tailored and optimized for the detection of each individual MRM transition, 
whereas full scan methods are restricted to one fixed set of parameters for all analytes, 
which may be suboptimal for the ionization and fragmentation of certain metabolites. In 
practice, even optimized MRM transitions may not represent a unique mass signature for 
a metabolite, as there are cases where multiple analytes present in a biological sample 
share the same transition. For example, indole 3-acetamide shows a strong signal for the 
175 → 130 transition, as does arginine, a highly abundant amino acid. This overlap in 
MRM transitions by different compounds underscores the critical importance of 
chromatographic separation in identifying metabolites. Another common problem that 
potentially compromises specificity is the tendency for metabolites possessing thermally 
labile bonds to decompose due to heated electrospray ionization (HESI). For example, a 
sample containing only high-purity TRP showed a strong signal for the indole transition 
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(118 → 91) at the same retention time as TRP (Fig. 3.6B), presumably due to partial 
decomposition into indole at the ion source.  
 To our knowledge, this is the first study to use MRM to quantify physiological 
concentrations of microbiota-produced metabolites present in intestinal tissue extracts. 
While the literature on absolute concentrations of microbiota metabolites is relatively 
sparse, we found good agreement between our results and previously reported values. In 
an early study, Whitt and coworkers used an enzymatic assay to determine an indole 
concentration of ~40 nmol/g tissue in murine cecum (168), which is comparable to our 
results (16 - 31 nmol/g tissue in cecum of young mice). The earlier study also reported 
that indole was absent in the cecum of germ-free mice, which is consistent with our 
pathway analysis algorithm’s prediction that indole is a product of bacterial metabolism. 
A comparison of samples from young and old mice suggests that the age of the host 
impacts the levels of microbiota metabolites in the GI tract as reflected in cecum and 
fecal concentrations of bacterial TRP derivatives. This observation is consistent with 
several recent studies showing that age may influence levels of other microbiota-
associated metabolites. For example, Vaahtovuo and coworkers reported differences in 
bacteria-derived cellular fatty acids in stool samples between 5 - 7 and 15 - 19 weeks old 
mice (169).  
 The AhR is a ligand-activated transcription factor that plays an important role in 
the mucosal immune system (71), and several TRP-derived chemicals have been 
identified as AhR ligands (81). In our study, we observed that three of the predicted TRP 
derivatives (indole 3-acetate, tryptamine and indole 3-pyruvate) were able to activate 
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AhR in a dose-dependent manner (Fig. 3.8, Fig. 3.9). This result is consistent with a 
previous study by Heath-Pagliuso et al., who showed that tryptamine and indole-3-
acetate function as AhR agonists (83). However, this previous study, while assuming 
that these two metabolites could be derived from TRP through enzymatic reactions, did 
not confirm that they are actually present in the GI tract in quantifiable amounts. In this 
work, we show that putative AhR agonists like tryptamine and indole-3-acetate are 
present in the cecum at intracellular concentrations (i.e., the levels present in the cecal 
bacteria and the surrounding tissue) ranging from 1 to 5 μM, and that they activate the 
AhR in vitro at concentrations of ~100 μM. This apparent discrepancy between the 
measured concentration of metabolites and the concentrations required to activate the 
AhR in vitro could be due to two reasons. First, the measured concentration of these 
metabolites is a conservative estimate, as it does not account for the metabolite 
extraction efficiency. Second, the concentrations needed to activate the AhR in vitro are 
extracellular concentrations (i.e., concentrations in the culture medium), and since the 
AhR is an intracellular (cytosolic) receptor, the extracellular medium concentrations may 
not equate to intracellular levels, depending on the rates of uptake and metabolism inside 
the cells. Further analysis is needed to model the kinetics of ligand uptake and 
processing that lead to the activation of the AhR. 
 An obvious extension of this work is to predict and identify molecules that can 
be derived by the intestinal microbiota from different source metabolites. One such 
source metabolite could be the amino acid phenylalanine that is reduced in the serum of 
germ-free mice, and therefore, a source of putative bioactive molecules. The 
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methodology described here can also be applied to identifying bioactive derivatives of 
environmental contaminants such as bisphenol A that can be generated in vivo by the GI 
tract microbiota and either have increased activity or have potentially different spectrum 
of activity (170).   
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CHAPTER IV 
ANALYSIS OF TRANSCRIPTION FACTOR NETWORK UNDERLYING 3T3-
L1 ADIPOCYTE DIFFERENTIATION 
 
4.1 INTRODUCTION 
Obesity is characterized by an increase in body fat mass, specifically in that of 
white adipose tissue (WAT) (14). Expansion of the body fat mass can occur either due to 
an increase in the number of adipocytes and/or an increase in size of adipocytes. The 
increase of adipocyte cell size is an important component of the increase in adipose 
tissue mass (15). Adipocyte enlargement arises as a result of genetic or environmental 
conditions that progressively increase lipid loading and therefore, cell size. The lipid 
content in adipocytes at any point is the result of a balance between formation and 
breakdown of lipid droplets in adipocytes. This lipid balance is extremely important as 
both high and low lipid levels have deleterious consequences. Several in vitro and in 
vivo studies (171-173) have shown that increased lipid loading and enlarged adipocytes 
correlate strongly with complications of obesity (e.g., recruitment of macrophages and 
inflammation, insulin resistance). Similarly, inadequate lipid levels in adipocytes are 
also not desirable as it leads to metabolic disorders and imbalance in supply of energy 
substrates to other organs such as the liver as well as insulin resistance (174). Therefore, 
control and regulation of the lipid balance in adipocytes (e.g., the ability to control lipid 
accumulation without significantly altering the extent of adipogenesis) is extremely 
important. 
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The enzymes mediating adipocyte lipid accumulation and utilization are 
regulated through the temporally coordinated action of several transcription factors (175, 
176).  In vitro studies have shown that during the clonal expansion of growth-arrested 
preadipocytes the expression of CCAAT/enhancer binding protein β (C/EBPβ) and δ 
(C/EBPδ) is increased (87). Subsequently, expression of peroxisome proliferator 
activated receptor- γ (PPARγ) and C/EBPα are stimulated (177). PPARγ is a master 
switch for adipocyte differentiation (176, 178), and along with sterol regulatory element 
binding protein-1c (SREBP-1c), directly controls the expression of several genes in 
lipogenesis. C/EBPα and C/EBPβ also sequentially regulate the expression of 
diacylglycerol acyltransferase 2 (DGAT2), which catalyzes the final step in 
triacylglycerol (TG) synthesis and lipogenesis, while PPARγ also regulates the 
expression of lipases (adipose triacylglycerol lipase, ATGL) that functions in lipid 
breakdown. In addition, SREBP-1c promotes adipogenesis. Although SREBP-1c cannot 
initiate adipogenesis by itself (179), it can activate PPARγ expression (180) which leads 
to an increase in adipogenesis. Cyclic AMP response element binding protein (CREB) is 
another early-transcriptional regulator as compounds that upregulate CREB activity 
(e.g., insulin, dexamethasone) also induce differentiation (175). Nuclear factor of 
activated T cells (NFAT) was demonstrated to form a composite enhancer complex with 
C/EBP and potentiate PPARγ expression (181), while the forkhead transcription factor 
(FoxO1) has been shown to counter PPARγ activation in 3T3-L1 adipocytes (182). 
While these studies have identified roles for different transcription factors, data from 
these studies provide limited information on both expression dynamics and interaction 
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between regulatory network molecules generated in these studies. In fact, simple 
inhibition of individual regulatory molecules often has adverse effects; for example, the 
inhibition of PPARγ in vivo reduces adipogenesis, but also increases insulin resistance, 
one of the chief complications of type-2 diabetes mellitus (183). Therefore, it is 
important to consider the dynamics and interaction between different members of the 
regulatory network for modulating complex phenotypes such as lipid balance in 
adipocytes. 
  In this study, we developed an integrated network model of adipocyte 
transcription factors based on published connections between the different molecules, 
and validated it using measurements of activation dynamics during adipocyte 
differentiation and lipid loading. The model was verified by perturbing the activation 
levels of CREB and determining its effects on the other transcription factors. The 
transcription factor network is expected to provide a framework for manipulating 
adipocyte differentiation and lipid accumulation during obesity. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 MATERIALS 
  3T3-L1 cells were kindly provided by Prof. Barbara Corkey (Boston University 
School of Medicine, MA). Tissue culture reagents including Dulbecco's Modified 
Eagle's Medium (DMEM), calf serum (CS), fetal bovine serum (FBS), human insulin, 
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and penicillin/streptomycin were purchased from Invitrogen (Carlsbad, CA). Unless 
otherwise noted, all other chemicals were purchased from Sigma (St. Louis, MO). 
 
4.2.2 CELL CULTURE AND DIFFERENTIATION 
 3T3-L1 cells were seeded in 6-well tissue culture plates in preadipocyte growth 
medium consisting of DMEM supplemented with CS (10 % v/v), penicillin (200 U/ml) 
and streptomycin (200 μg/ml). Medium was replenished every other day. Two days post-
confluence, differentiation was induced using a standard adipogenic cocktail (1 μg/ml 
insulin, 0.5 mM isobutylmethylxanthine, and 1 μM dexamethasone) added to a basal 
medium (DMEM with 10 % FBS and penicillin/streptomycin). After 48 h, the first 
differentiation medium was replaced with a second differentiation medium consisting of 
the basal adipocyte medium supplemented with only 1 μg/ml of insulin. After another 48 
h, the second medium was replaced with the adipocyte basal medium and replenished 
every other day.  
 
4.2.3 CONSTRUCTION OF GAUSSIA LUCIFERASE REPORTER PLASMIDS  
Lentiviral reporter plasmids for monitoring activation of six transcription factors 
(TFs) - PPARγ, SREBP-1c, NFAT, CREB, C/EBPβ and FoxO1 - during adipocyte 
differentiation and lipid loading were constructed as described below. For each TF, 
consensus binding sites (response elements; RE) in target gene promoter regions were 
identified using TRANSFAC database 7.0 Public (AGGACAAAGGTCA for PPARγ, 
CATGTG for SREBP-1c, GGAAAATTTGAGTCA for NFAT, TGACGTCA for CREB, 
 67 
 
ATTGCGCAAT for C/EBPβ and AGTTGGACGCGAC for FoxO1). Response element 
(RE) oligonucleotides containing the binding sequence for each TF were chemically 
synthesized. Each RE oligonucleotide consists of three consensus binding sequences 
separated by 4 - 6 bases (spacer sequence) and a unique restriction enzyme (EcoRI and 
AfeI) cleavage sites at the ends. The RE oligonucleotides were cloned into Gluc-DRE2-
viral vector (pCS-sMAR8-pA1-DRE2-hPGK-cHS4-tACTB-SPA-Gluc-CMVmin) (184) 
in which expression of the Gaussia luciferase (Gluc) is under the control of a minimal 
promoter. Expression of Gluc is induced only when a TF binds to its consensus binding 
site. Clones containing the correct RE were identified by multiple restriction enzyme 
digests and sequenced to verify fidelity.   
 
4.2.4 GENERATION OF STABLE REPORTER CELL LINES  
Stable reporter cell lines for each TF were generated by lentiviral transduction. 
To produce lentiviral particles, each TF reporter plasmid and two helper plasmids 
(psPAX; Addgene plasmid 12260 and pMD2.G; Addgene plasmid 12259, Dr. Trono, 
Lausanne, Switzerland) were co-transfected into 293T/17 cells using the calcium 
phosphate transfection method (185). After 24 h following the transfection, the medium 
was replenished and 5 mM of sodium butyrate was added, and incubated for an 
additional 24 h. Supernatants containing viral particles were collected, pooled, filtered 
with 0.45 μm filters, and centrifuged for 2 h at 4°C at 48000 xg. The viral titer was 
measured using a Lenti-X qRT-PCR titration kit (Clontech, Palo Alto, CA). To 
transduce 3T3-L1 preadipocytes, concentrated virus particles (~ 2 x 10
8
 IFU) were added 
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to the cells in presence of Polybrene (hexadimethrine bromide). The cells were incubated 
with the virus particles for 15 h, and the medium was replenished the next day. The 
efficiency of transduction was assessed by microscopic analysis.  
 
4.2.5 VALIDATION OF REPORTER PLASMID FUNCTION  
  Plasmids for constitutive expression of the TFs were purchased from Addgene 
(pCMV5-FLAG-FoxO1, pSV Sport SREBP-1c, pEGFP-C1 NFAT3, pcDNA flag PPAR 
gamma) or Invitrogen (pCMV-Sport6-CREB). 293T/17 cells were seeded in 6-well 
tissue culture plates, and ~1 μg of each expression plasmid was cotransfected along with 
the corresponding reporter plasmid (~ 1 μg) using the calcium phosphate transfection. 
For control experiments, the same amount of pEYFP-N1 plasmid (constitutive 
expression of yellow fluorescent protein) was transfected. At 48 h post-transfection, 
supernatants were collected and luciferase activity measured using the BioLux Gaussia 
Luciferase Flex assay kit (New England Biolabs, Ipswich, MA). Additionally, the 
PPARγ reporter plasmid was validated using thiazolidinedione (TZD) as the agonist. 
PPARγ was overexpressed from plasmid (pcDNA flag PPAR gamma) in 3T3-L1 PPARγ 
reporter cells and 25μM TZD was used to activate PPARγ for 24 h. The C/EBPβ 
reporter cell line was validated by up-regulating C/EBPβ with 100 ng/mL oncostatin M 
(OSM) for 12 h (186). Luciferase activity in the supernatant was determined as 
described above.  
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4.2.6 MEASUREMENT OF TRANSCRIPTION FACTOR ACTIVITY PROFILES  
For profiling TF activation in each reporter cell line, 3T3-L1 preadipocyte 
reporter cells for each TF were seeded in 6-well tissue culture plates and differentiated 
into adipocytes as described above. At different stages post-differentiation, 30 µL 
supernatant samples were collected at 24 h post-medium change from day 0 (induction 
of differentiation) until day 17. Samples were stored at -20°C prior to assessing 
luciferase activity. The luciferase activity (Relative Light Units; RLU) measured was 
used to calculate the rate of Gluc production (RLU divided by the time over which Gluc 
was secreted). To account for differences in cell density between different experiments, 
the RLU rate was normalized with the red fluorescence intensity (Relative fluorescence 
units; RFU) measured at 550 nm (excitation) and 600 nm (emission). The fold-increase 
in TF activity was determined by normalizing the (RLU/h)/RFU at each time point to the 
corresponding value at the start of differentiation (i.e., day 0).      
 
4.2.7 PERTURBATION OF THE TRANSCRIPTION FACTOR NETWORK BY 
FORSKOLIN 
 CREB, C/EBPβ and PPARγ reporter cell lines were seeded in 6-well tissue 
culture plates and differentiated into adipocytes as described above. Cells were treated 
with 10 μM of forskolin or 0.1% DMSO at day 0 for 48 h. TF-driven luciferase activity 
in the supernatants was determined and the TF activation profiles were determined as 
described above. 
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4.2.8 TRANSCRIPTION FACTOR NETWORK  
 An interaction network model of the TFs analyzed in this study was assembled 
from the published literature (87, 90-93, 104, 180, 182, 187). A schematic of the model 
is shown in Fig. 4.1. The model included only four of the six measured TFs, i.e. CREB, 
C/EBP, PPARγ, and SREBP-1c, as interactions involving the other two TFs, NFAT and 
FoxO1 were not consistently documented in the literature. The guiding principles in 
assembling the model were simplicity and identifiability. While it is likely that some of 
the TFs interact with each other through intermediaries and co-activators, these 
molecules were not experimentally monitored in this study, and thus it was not 
attempted to model these details. Including additional details could have improved the fit 
of the model to the data by increasing the degree of freedom, but the “improved” fit 
would have occurred at the expense of diminished identifiability. For these reasons, the 
activation of a TF by another factor was assumed to occur directly, and modeled using 
simple mass action kinetics. The exception was the activation of PPAR by SREBP-1c, 
which was assumed to involve the induction of a metabolic enzyme leading to the 
production of an activating ligand. The identity of this ligand remains to be definitively 
established, and a number of candidates have been proposed such as 13-
hydroxyoctadecadienoic acid, 15-hydroxyeicosatetraenoic acid and 1-O-hexadecyl-2-
Azelaoyl-sn-glycero-3-phosphocholine (188, 189); however, there is reasonable 
consensus that SREBP-1c activation of PPAR involves the endogenous production of a 
metabolite ligand. Including the putative PPAR ligand, the TF network model    
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Fig. 4.1. Schematic of TF network model. Arrows indicate direction of interaction. 
Model parameters (k2, k5, k8, and k10) labeling dotted arrows represent first-order 
decay rate constants for the TFs. See text for abbreviations.  
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comprises 5 species whose levels varied continuously with time. In addition, the model 
included three input species representing the differentiation inducing hormones insulin, 
dexamethasone (DEX), and isobutylmethylxanthine (IBMX). The levels of these input 
species were set to one (arbitrary units) or zero to reflect the addition and withdrawal of 
the hormones at different stages of a differentiation experiment. For the initial induction 
period from time zero to 48 h, the levels of all three input species were set to one. For 
the second induction period from 48 h to 96 h, DEX and IBMX were set to zero, while 
insulin was kept at one. For the maintenance period from 96 h to end of the experiment, 
all input species were set to zero.  
The rates of change of the 5 time variant species were described using ordinary 
differential equations (ODEs). Partial differentiation equations or stochastic equations 
were not considered, because the data collected reflected the pooled averages of many (> 
10
6
) cells in a well-mixed environment. The general structure of the ODEs describing 
the TF dynamics was as follows. 
   
  
 ∑     
 
                                                                 
In equation (1), yi is the amount of active TF i, yj is the amount of a TF j that activates i, 
and kj>i is the rate constant for first-order activation of i by j. Every TF was assumed to 
decay at a rate proportional to its amount with a first-order degradation rate constant kd. 
The rate of production and degradation of the metabolite ligand was modeled similarly 
using first-order rate expressions. The full set of ODEs describing the dynamics of the 
TFs and ligand are listed in Table 4.1.  
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Table 4.1. Mass action kinetic model of TF interactions  
 
TF (or 
Ligand) 
Differential equation k min max median 
CREB 
1 2
dCREB
k IBMX k CREB
dt
   
k1 1.04E+01 1.50E+01 1.26E+01 
k2 8.65E-01 1.18E+00 9.93E-01 
C/EBP 4 3 7 5
dCEBP
k DEX k CREB k PPAR k CEBP
dt
   
 
k3 5.99E-07 2.25E+01 2.42E+00 
k4 2.17E-09 3.89E+00 1.65E+00 
k5 5.00E-01 8.79E+01 1.05E+01 
k7 9.12E-02 2.38E+01 2.96E+00 
PPAR 
6 12 8
dPPAR
k CEBP k Ligand k PPAR
dt
    
k6 3.43E-01 3.85E+01 1.50E+01 
k8 5.00E-01 5.35E+01 2.35E+01 
k12 2.27E-01 4.32E-01 2.82E-01 
SREBP-
1c 9 13 10
dSREBP
k Insulin k PPAR k SREBP
dt
    
k9 2.72E-01 1.56E+00 4.22E-01 
k10 8.61E-02 1.40E+00 2.52E-01 
k13 1.29E-08 4.74E-01 5.62E-02 
Ligand 
11 12
dLigand
k SREBP k Ligand
dt
   k11 8.37E-01 1.00E+02 4.89E+01 
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4.2.9 PARAMETER ESTIMATION 
 The model parameters, i.e. rate constants, were estimated from the 
experimentally obtained TF time course data (control condition without forskolin 
treatment) using a nonlinear constrained optimization procedure. The objective function 
was to minimize the sum of squared residuals (SSR) measuring the discrepancy between 
the measured and calculated TF levels for all time points. 
   ∑∑     
        
                                                           
  
 
In the above expression, yi,t refers to the ith TF activity level (in RLU/h/RFU) at time 
point t, with the superscript denoting experimentally measured or model calculated 
value. The optimization variables were the rate constants k1 through k14 describing 
activation (production) or degradation of the 5 model species (Table 4.1). The 
experimental data were averages of two independent experiments, where each 
experiment included two biological replicates for each TF. Parameter optimization was 
iterated 50 times. Each time, randomly generated noise drawn from a normal distribution 
was added to the experimental data. A noise level of 5 % standard deviation was used 
based on average variances in the measured TF activities across replicate experiments. 
For each of the 50 iterations, the optimization was repeated 5 times using a randomly 
generated set of initial parameter values. The upper bounds were set to 100 to ensure that 
the first-order rate parameters are within one order of magnitude from the observed rates 
of increase or decrease. The lower bounds on the TF degradation rate constants (k2, k5, 
k8 and k10) were set to 0.5, to ensure that there is a finite degradation rate for each of the 
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factors. We chose a minimal rate constant value that is equivalent to a half-life of ca. 36 
h, which is 5- to 10-fold longer than the reported half-lives of TF modeled in this study. 
The lower bounds on all other parameters were set to zero. The initial values of the TFs 
were set to one (‘1’) to reflect the normalization of the experimental data. The initial 
value of the metabolite ligand was set to zero, as it was assumed that the ligand is not 
present in preadipocytes prior to induction. The optimization was performed using the 
LSQNONLIN function (trust-region-reflective method) of the Optimization Toolbox in 
MATLAB (Natick, MA). 
 
4.2.10 SIMULATION OF THE TRANSCRIPTION FACTOR NETWORK  
 The TF network described above was evaluated by comparing the simulated TF 
time profiles against experimental data from a perturbed condition, i.e. forskolin 
exposure, which was not used in estimating the parameters. Model simulations were 
performed using all 50 sets of parameters, leading to 50 different sets of TF time 
profiles. Addition of forskolin, which rapidly increases intracellular cAMP (190), was 
modeled as step increase in IBMX during the first induction period (time 0 to 48 h) from 
a value of 1 to 1.7. This step increase in IBMX was set based on the measured profile of 
CREB, which is the direct target of IBMX in the model. All other model parameters and 
initial values were the same as the parameter estimation problem.  
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4.3 RESULTS  
 
4.3.1 GENERATION OF GAUSSIA LUCIFERASE REPORTER CELL LINES 
TRACKING TRANSCRIPTION FACTOR ACTIVITY  
  A panel of six transcription factors (TFs) (PPARγ, SREBP-1c, NFAT, CREB, 
C/EBPβ and FoxO1) was chosen to develop a regulatory network underlying adipocyte 
differentiation and lipid loading. Reporter plasmids were developed as described in 
Materials and Methods and validated by determining if activation of a transcription 
factor led to expression of the Gaussia luciferase gene from the reporter plasmid. For the 
transcription factors CREB, SREBP-1c, NFAT, and FoxO1, plasmids containing the full 
length gene for each TF were over-expressed in 293T/17 cells by transfection along with 
the corresponding reporter plasmid. Figure 4.2A shows 5-30 fold increase in luciferase 
activity when transcription factors were overexpressed for 48 h. The 3T3-L1 PPARγ 
reporter cell line was validated by over-expressing PPARγ and activating it with a 
chemical agonist, thiazolidinedione (TZD). Figure 4.2B shows that overexpression of 
PPARγ increases PPARγ-driven luciferase activity by 1.3-fold, and additional 
stimulation with 25 µM TZD resulted in a 1.5-fold increase in luciferase activity. The 
C/EBP reporter was validated by stimulating 3T3-L1 preadipocyte C/EBPβ reporter 
cells with the cytokine oncostatin M (OSM), which resulted in a 1.7 fold increase in 
C/EBPβ-driven luciferase activity (Fig. 4.2C). Together, these results confirmed the 
ability of the developed reporter cell lines to report activation of the different TFs. 
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Fig. 4.2. The six TF reporter constructs properly present activation of each target TF. 
(A) When plasmids for constitutive expression of TFs were cotransfected with 
corresponding reporter plasmids into 293T/17 cells, Gluc activities were induced. (B) 
When a plasmid for constitutive expression of PPARγ was transfected into 3T3-L1 
PPARγ reporter cells, there was 1.5 fold increase of Gluc activity. Treatment of a 
PPARγ agonist (TZD) contributed to 1.3 fold increase. (C) Treatment of a C/EBPβ 
agonist (OSM) on 3T3-L1 C/EBPβ reporter cells caused 1.7 fold increase. Data 
represent mean ± SD. 
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Fig. 4.3. 3T3-L1 PPARγ reporter cells after 19 days of induction for differentiation 
(A) transmitted light (B) red fluorescence microscopy images. 
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Lentivirus-mediated integration of the reporter plasmids into 3T3-L1 
preadipocytes did not affect the ability of the different reporter cells to differentiate into 
adipocytes. Figure 4.3 shows representative transmitted light and red fluorescence 
images of the PPARγ reporter cell line after 19 days in culture, and clearly demonstrate 
that adipocyte differentiation was not affected (i.e., reporter cells show comparable 
accumulation of lipid droplets and cell morphology to 3T3-L1 adipocytes without the 
reporter plasmid). Moreover, no differences in differentiation and lipid loading were 
observed between the different reporter cell lines (Fig. 4.4). In addition, more than 90% 
of reporter cells demonstrated RFP expression, and suggest proper integration of the 
reporter DNA.  
 
4.3.2 PROFILES OF TRANSCRIPTION FACTOR ACTIVITY DURING 
ADIPOCYTE DIFFERENTIATION AND ENLARGEMENT 
3T3-L1 preadipocyte reporter cells were differentiated into adipocytes and the 
activity of each TF was monitored throughout the differentiation and maturation process. 
The different TFs demonstrated markedly different activation dynamics. As shown in 
Fig. 4.5, CREB reporter cells demonstrated a pronounced 13-fold increase in normalized 
luciferase activity (RLU/h/RFU) on day1 after addition of differentiation media. 
However, this increase was transient as the normalized luciferase activity rapidly 
decreased and returned to day 0 levels by day 7. On the other hand, PPARγ reporter cells 
demonstrated a 3-fold increase in luciferase activity in the first 24 h after induction of 
differentiation. However, unlike CREB, this increase was sustained, as nearly 2-fold  
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Fig. 4.4. 3T3-L1 TF reporter cells after 19 days of induction for differentiation.  
Transmitted light images of (A) FoxO1, (C) CREB, (E) NFAT, (G) SREBP-1c and 
(I) C/EBPβ and red fluorescence images of (B) FoxO1, (D) CREB, (F) NFAT, (H) 
SREBP-1c and (J) C/EBPβ.  
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Fig. 4.5. TF activity profiles represented as fold of increase rates of Gaussia 
luciferase (Gluc) activities normalized with relative fluorescence units (RFU). The 
Gluc activities which reflect a degree of each TF binding onto response elements 
were measured every 24 h post-medium change from a time point of differentiation 
induction (day 0) to day 17. The increase rate of Gluc activity (RLU/h) was 
normalized with relative fluorescence units (RFU). The fold of the increase rate of 
Gluc activity was determined by normalizing the RLU/h/RFU at each time point to 
the corresponding value at the start of differentiation (i.e., day 0). Data represent 
mean ± SD. 
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higher activation of PPARγ was observed until day 17 post-differentiation compared to 
that in preadipocytes. This trend was especially noticeable beyond day 7 post-
differentiation. C/EBPβ, SREBP-1c, NFAT and FoxO1 all demonstrated similar 
activation dynamics with maximum activation observed at day 1 until day 3 and 
gradually decreasing to near-baseline values after day 5.  
 
4.3.3 SIMULATION OF TRANSCRIPTION FACTOR ACTIVITY PROFILES 
Based on literature reports, a simple network model was assembled describing 
the interactions between TFs as well as their stimulation by adipogenic hormones (Fig. 
4.1). Only a subset of the TFs (CREB, C/EBPβ, PPARγ, and SREBP-1c) was considered, 
as the interactions involving NFAT and FoxO1 were less clearly documented. Activation 
and decay of TFs were modeled using mass action kinetics (Table 4.1). The model’s rate 
parameters were fitted to the normalized activity profiles shown in Fig. 4.5 by 
minimizing the sum of squared residuals (SSR) between the measured and model-
calculated TF activity profiles.  
 Across 50 iterations of parameter optimization, the SSR varied from 4.82 to 7.22, 
with a mean value of 5.99. The mean values of the optimized parameters ranged from 
10
0
 to 10
1
, in terms of order of magnitude, except for the rate constant describing 
activation of SREBP-1c by PPARγ (k13). The estimated value of this rate constant 
ranged from 0 to 0.47 across the iterations, with a mean value of 0.06 and standard 
deviation of 0.12, indicating that this parameter is not statistically significantly greater 
than 0 (one-sided t-test, p > 0.05). A majority of the parameters were reasonably well 
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constrained, as assessed by the ranges of the values obtained across the iterations of 
parameter optimization (Table 4.1). The parameters with the greatest uncertainty were 
associated with the degradation rate of C/EBPβ (k5) and the production rate of the 
putative ligand for PPARγ (k11), as their estimated values ranged from 0.5 to 87.9 and 
0.8 to 100, respectively. Given the uncertainties in the estimated parameters, model 
simulations were performed using all of the 50 sets of optimized parameters to obtain 50 
sets of profiles from which means and standard deviations were calculated (Fig. 4.6).  
Overall, the simulated profiles were largely consistent with the measured profiles, 
and correctly ordered the peak activities for the TFs. Importantly, the simulations 
showed a sustained elevation in PPARγ activity that extends to day 11, in good 
agreement with the measured profile. On the other hand, there were noticeable 
differences between the shapes of the measured and simulated profiles. The rise and fall 
of the simulated profiles were generally somewhat sharper, presumably due to the 
simplifying assumptions regarding the concentrations of the hormones, which were 
modeled as step inputs. Specifically, the simulated profile for C/EBPβ showed an 
initially sharp rise until day 2, followed by a rapid decline, whereas the measured profile 
showed a broader peak extending from day 1 to day 5. In addition to the assumption 
regarding step change in the hormonal input levels, it is also possible that the 
discrepancy could be due to the fact that the C/EBPβ reporter cannot discriminate 
between other isoforms of C/EBP.  
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  Fig. 4.6. Simulated profiles of TF dynamics. Simulations were performed with each 
of the 50 sets of parameters estimated from the measurement profiles. The average 
profiles are shown in bold solid lines, with error bars representing one standard 
deviation across the 50 simulations. Red circles indicate measured TF activities.  
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4.3.4 PERTURBATION OF THE TRANSCRIPTION FACTOR NETWORK BY 
FORSKOLIN TREATMENTS  
In order to evaluate the TF network model, we perturbed the activity of CREB 
using forskolin, and investigated its effects on the activation of C/EBPβ and PPARγ. In 
the simulations, this perturbation was modeled as an increase in the concentration of 
IBMX relative to the unperturbed condition. As shown in Fig. 4.7, forskolin treatment on 
day 0 resulted in 1.7-fold increase in the maximum activation of CREB as compared to 
the control, while retaining the same activation dynamics. The maximum activation of 
C/EBPβ and PPARγ increased 1.3-fold and 1.5-fold, respectively, after forskolin 
treatment. These results are largely consistent with the model simulations, which also 
showed a positive, but attenuated fold-change in the C/EBPβ and PPARγ activities 
relative to the unperturbed condition (Fig. 4.8). When the average maximum activity of 
CREB (on day 1) was increased to 1.8-fold in the simulation (relative to the unperturbed 
simulation) by adjusting the initial IBMX input level, the corresponding increases in the 
C/EBPβ and PPARγ maximum activities (based on the averages of the simulated profiles) 
were 1.3-fold and 1.2-fold, respectively.   
 
4.4 DISCUSSION  
In this study, we developed an integrated transcription factor (TF) network model 
underlying adipocyte differentiation and enlargement and validated it using dynamic 
activation profiles of different TFs during differentiation of preadipocytes into 
adipocytes and lipid accumulation. Dynamic activation profiles of the different TFs were     
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Fig. 4.7. Perturbation of CREB activity profiles by forskolin treatments. Cells were 
treated with 10 μM of forskolin or 0.1% DMSO at day0 for 48 h. For each time 
point, fold of RLU/h/RFU was calculated by dividing with a value of day 0. Data 
represent mean ± SD. *: p < 0.05  
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  Fig. 4.8. Simulations of TF activity profiles representing the forskolin treatment 
(dashed blue line) and vehicle control (solid black line) conditions. 
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obtained using 3T3-L1 reporter cell lines where binding of a transcription factor to its 
recognition sequence leads to expression of a Gaussia luciferase reporter gene. Since the 
luciferase gene has a secretion leader sequence, non-invasive dynamic profiling of TF 
activity is possible by monitoring the culture supernatant for luciferase activity. This 
approach enabled us to directly monitor TF function (i.e., binding to its recognition 
sequence) as opposed to inferring activity from mRNA and protein data. The non-
invasive measurement technique also allows for frequent sampling, which, in turn, 
facilitates data-based model construction. Lastly, this approach also allows for TF 
activation profiles to be derived from the same population of cells over the 
differentiation and maturation.   
The differentiation of 3T3-L1 preadipocytes into mature adipocytes is 
characterized by accumulation of lipid droplets and alteration of cell shape which are 
mediated by multiple enzymes and regulatory TFs. While previous data on the activation 
of different TFs underlying adipocyte differentiation and enlargement are available in 
the literature, differences in the experimental conditions and readout methods limit their 
utility for developing an integrated network model. In this study, we address this by 
developing a TF model using time-course data from the same cell population. 
Our results show that different TFs demonstrate distinct activation profiles 
during adipocyte differentiation and enlargement, which are consistent with published 
reports. The temporal correlation between CREB and C/EBPβ is one such example (Fig. 
4.5) where activation of C/EBPβ follows the activation of CREB until day5. Zhang and 
coworkers (104) have demonstrated that CREB induces expression of C/EBPβ at 8 h 
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after induction of the adipogenic program. Similarly, SREBP-1c has been shown to 
promote adipogenesis by generation of a PPARγ ligand (179), and it has been proposed 
that SREBP-1c could activate expression of PPARγ by binding to a PPARγ promoter 
(180). NFAT has also been proposed as a regulator of PPARγ activity since NFAT 
associates physically with PPARγ (187). Our data show that both SREBP-1c and NFAT 
show comparable activation profiles as C/EBPβ, which is known to precede and activate 
expression of PPARγ (191), during the initial differentiation phase(days 1-3). Thus, our 
data provide corroborating evidence for SREBP-1c and NFAT in regulating PPARγ 
activity. PPARγ is a key TF which plays critical roles for induction and maintenance of 
fully differentiated adipocytes. Our data also show that PPARγ activity increased 
gradually from the induction of differentiation and stayed elevated between days 7 and 
11. While the activation levels decreased after day 11, they were still significantly higher 
than baseline (preadipocyte) levels for the duration of the experiment. Interestingly, only 
PPARγ demonstrated sustained activation as the activity of other TFs decreased to pre-
induction levels after adipocyte maturation (days 7-10). This result is consistent with the 
primary role for PPARγ in adipocyte differentiation and enlargement. Interestingly, 
FoxO1 did not show significant activation over the time course of the experiment. A 
recent study has shown that a direct protein-protein interaction leads to repression of 
PPARγ activity by FoxO1 (192). However, since FoxO1 interferes with PPARγ by 
recruitment to the PPARγ response element, measurement of FoxO1 binding to its own 
response element may not show any correlation to alterations in PPARγ activity. 
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To more quantitatively characterize the interactions between TFs regulating the 
adipocyte differentiation program, we assembled a mass action model of TF activation 
and decay based on connections documented in the published literature. For four of the 
TFs monitored in this study, namely CREB, C/EBPβ, PPARγ, and SREBP-1c, there was 
a general consensus regarding the activation cascade. For the sake of parsimony, we 
modeled the cascade as a sequence of direct activation events between TFs. The sole 
exception was the activation of PPARγ by SREBP-1c, as there was strong evidence that 
SREBP-1c activation induces the production of a metabolite ligand for PPARγ (103). As 
published data on adipocyte TF network activation rates were not available, the rate 
parameters were estimated from the measured profiles collected in this study. Outside of 
the general assumption that the rate constants have to be nonnegative, the only other 
constraint applied to the parameters was to set a lower bound for the turnover rates of the 
TFs.  The estimated decay rate constants were significantly higher than the lower bound, 
ranging from ~1 day
-1
 to ~23 day
-1
. These decay rate constants correspond to half-life 
ranges of ~17 h to ~40 min, which are comparable to published turnover rates of TFs 
(193-198). As alluded to earlier, there is substantial uncertainty regarding the estimated 
decay rate constant for C/EBPβ. One possible explanation is that the reporter construct 
measured not only C/EBPβ, but also the other isoforms of the C/EBP family. In 
particular, the measured profile could reflect the activation of C/EBP, which follows 
the earlier activation of the β and  isoforms during the initial stages of adipogenesis. 
Conflating the , β and  isoforms could lead to an apparent broadening of the peak TF 
activity period, as the decline in the β and  isoforms could be masked by the rise in the 
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 isoform. It is thus possible that two distinct sets of activation and decay rates, and 
correspondingly discriminatory measurements, may be needed to more accurately model 
the dynamics of C/EBP. 
The other large uncertainty in parameter estimation involved the production rate 
of the PPARγ ligand upon induction of SREBP-1c. Similar to the C/EBP decay rate 
parameter, the simplest explanation is the lack of direct and specific experimental 
observations on the dynamics of the putative ligand. Moreover, it is likely that multiple 
ligands are produced in differentiating adipocytes (199), although a dominant 
endogenous ligand has not yet been conclusively identified. Another, related limitation 
regarding the interpretation of the simulated ligand time profile is that it is not possible 
to determine an absolute concentration range for the ligand, because normalized TF time 
profiles were used in fitting the model.  
Despite these limitations, the mathematical model revealed several noteworthy features 
of the adipocyte TF network. First, model simulations of forskolin stimulation showed 
that an increase in CREB activity is attenuated as the stimulus propagates to C/EBP and 
PPARγ, indicating correct ordering of upstream and downstream TFs. This prediction 
was in good agreement with measured data, which also showed an attenuation of TF 
stimulation downstream from CREB. Second, the estimated values for rate parameters 
suggest that feedback activation of SREBP-1c by PPARγ is negligible in comparison to 
activation of SREBP-1c by insulin, corroborating the downstream placement of SREBP-
1c relative to PPARγ in recently published studies (200, 201). Third, the estimated 
parameters suggest that the strength of the positive activation loop between C/EBP and 
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PPARγ is comparable to the strengths of the activation cascades connecting the TFs to 
hormonal inputs. This finding is consistent with previous experiments showing that 
direct (e.g. genetic) manipulation of either C/EBP or PPARγ could drive the adipogensis 
program to similar extents as hormonal stimulation (93, 202).  
The integrated model of the TF network developed in this study provides a 
powerful tool for direct control of the entire regulatory network and further adipocyte 
metabolism. For example, we can predict overall change of activity profiles for key TFs 
triggered by a specific perturbation (i.e. agonist or antagonist) and its influence on 
expression levels of target genes which are regulated by the TFs. We expect the 
systematic understanding for the TF network will be a key basis to develop a new 
treatment against obesity. In addition, the combinatorial approach of experiment and 
simulation reported in this study will be applicable to understand complex networks in 
other cellular regulatory mechanisms.   
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CHAPTER V 
MECHANISMS UNDERLYING RECOGNITION OF TRYPTOPHAN 
DERIVATIVES IN HOST CELLS 
 
5.1 INTRODUCTION 
The human gastrointestinal (GI) tract consists of ~10
14 
bacteria belonging to 
~1,000 species which are collectively termed gut microbiota. Recently, the microbiota 
metaboliteshave been considered as important modulators of host physiology instead of 
metabolic byproducts. For example, our laboratory demonstrated that tryptophan (TRP)-
derived bacterial metabolite indole attenuates several inflammatory indicators in 
intestinal epithelial cells (IECs) (27). In addition, non-alcoholic fatty liver disease and 
cardiovascular diseases correlates with conversion of choline into trimethylamine by the 
gut microbiota (11, 12).   
In our prior work (Chapter  III), we predicted bacterial products of TRP 
metabolism by computational pathway analysis, and quantified physiological levels of 
the predicted metabolites in murine cecum and feces by utilizing multiple reaction 
monitoring (MRM) mass spectrometry. Further, the TRP derivatives were characterized 
as bioactive molecules by demonstrating agonist activity for aryl hydrocarbon receptor 
(AhR). However, the mechanisms underlying recognition of the TRP derivatives (i.e., 
the receptor(s) involved, the signaling pathways utilized) have not been elucidated yet. 
Identification of molecular signaling targets for the TRP derivatives is necessary to 
comprehensively understand the influence of the TRP derivatives on host cell function.    
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The AhRis a ligand-activated transcription factor that has been shown to play an 
important role in the intestinal immune system (70, 71). In the absence of ligand, AhR is 
localized in the cytoplasm. Upon ligand binding, AhR translocates into the nucleus 
where it heterodimerizes with the AhR nuclear translocator (Arnt) protein. The AhR-
Arnt complex specifically interacts with the dioxin response element (DRE) in promoter 
regions of various target genes and modulates their transcription. In addition, the AhR 
modulates target gene expression through interaction with nuclear factor-κB (NF- κB) 
p65 (203). The AhR interacts with a wide spectrum of diverse natural or synthetic 
compounds such as halogenated aromatic hydrocarbons, heterocyclic amines, polycyclic 
aromatic hydrocarbons and several indole containing compounds (75-77). Although 
many dietary compounds were initially suggested as natural ligands for AhR, several 
reports have indicated that endogeneous physiological ligands for AhR exist (78-80). For 
example, endogeneous metabolites of tryptophan such as tryptamine and indole acetic 
acid were shown to bind to and activate AhR (83). 
Several studies showed that synthetic 3,3’-diindolylmethane (DIM) derivatives 
(i.e., DIM-C-pPhCF3, DIM-C-pPhOCH3, DIM-C-Ph) activates NR4A1, a member of the 
nerve growth factor–induced B (NGFI-B) subfamily of orphan nuclear receptors (132, 
147).  The DIM is generated through heterodimerization of indole-3-carbinol in the acid 
environment of the gut (81) and exhibits anticancer activities through activation of the 
AhR (204). The NR4A subgroup consists of neuron-derived clone 77 (Nur77; NR4A1), 
nuclear receptor related 1 (Nurr1; NR4A2) and neuron derived orphan receptor 1 (NOR1; 
NR4A3). Recent functional studies have pointed a critical role of NR4A members in 
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control of inflammation. For example, NR4A2 represses transcription of TNFα and IL-
1β through recruitment of corepressor for element-1 silencing transcription factor 
(CoREST) complex to a target promoter and clearance of NF-κB (144). To date, 
endogenous ligands for NR4A receptors have not been identified. 
Dendritic cells (DCs) are specialized antigen presenting cells (APCs) that possess 
unique properties for adaptive immune responses. DCs migrate from peripheral tissues 
to lymphoid tissues in which they present antigens to T cells (205). DCs exist in 
functionally distinct immature and mature cells. The immature DCs in the peripheral 
tissues are mainly phagocytic cells while mature DCs in lymphoid tissues are 
characterized by high surface expression of co-stimulatory molecules for T cell 
activation (205). In the gut, DCs distribute in the lamina propria of the small and large 
intestine, the Peyers patch and mesenteric lymph nodes (206, 207). Intestinal DCs have 
been shown to drive development of regulatory T cells (Treg) which are essential to 
counteract inflammatory responses (208). In addition, intestinal DCs impart gut-homing 
properties to lymphocytes and induce B cells to acquire expression of IgA which 
supports several mucosal functions (206, 209). Although the exact role of DCs in 
intestinal disease is unknown, several observations in models of inflammatory diseases 
suggest that aberrant DCs derive dysregulated inflammation (210).     
The goal of this study is to elucidate the molecular recognition mechanism(s) 
underlying sensing on TRP derivatives and in anti-inflammatory function. In previous 
studies (70, 71, 141-144), both AhR and NR4A receptors have shown to play important 
roles in modulation of inflammation. Moreover, endogeneous metabolites of tryptophan 
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have shown to activate AhR, and synthetic derivatives of DIM retaining AhR activation 
have been demonstrated as NR4A agonists (83, 147). Therefore, we hypothesized that 
TRP derivatives are recognized by AhR and/or NR4A receptors and the sum of these 
interactions determines the extent of anti-inflammatory activity. Our data indicate that 
knockdown of NR4A2 attenuates, but not completely abolishes, the anti-inflammatory 
activity of indole to suppress expression of pro-inflammatory cytokine TNFα in 
dendritic cells. Our results suggest that NR4A2 is an anti-inflammatory signaling target 
of indole. In a future knockdown study of AhR, it will be clarified whether AhR also 
functions as a receptor for indole signaling.         
 
5.2 MATERIALS AND METHODS 
 
5.2.1 CELL CULTURE  
 The DC2.4 murine dendritic cell line was obtained from ATCC (Manassas, VA). 
DC2.4 cells were cultured at 37 °C with 5 % CO2 in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 5% (v/v) fetal bovine serum (FBS), glucose (3.5 
g/L), sodium bicarbonate (2 g/L), nonessential amino acids (0.1 mM), HEPES (10 mM), 
penicillin (100 U/ml) and streptomycin (100 μg/ml).  
 
5.2.2 WESTERN BLOT ANALYSIS  
 Whole cell lysates were extracted using RIPA buffer. The lysates were heated at 
100 °C for 5 min, separated on 4% to 20% SDS-PAGE (BIO-RAD, Hercules, CA) and 
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transferred to a nitrocellulose membrane (Invitrogen, Carlsbad, CA). The membrane was 
blocked with 5 % (v/v) nonfat dry milk in Tris-buffered saline overnight and incubated 
with a 1:500 dilution of anti-NR4A2 antibody (clone N-20) (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 1 h at room temperature. After washing for 15 min, a 1:5000 
dilution of a goat anti-rabbit IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA) 
was added, and the membrane was incubated for 45 min. After washing for 20 min, the 
membrane was incubated with a SuperSignal Kit (Pierce Chemical, Rockford, IL) for 5 
min and imaged using Bio-rad Model 3000 VersaDoc Imaging System. 
 
5.2.3 LENTIVIRUS PRODUCTION AND INFECTION OF DC2.4 CELLS  
293T/17 cells were seeded at 8 × 10
5 
cells per 6 well tissue culture plate in 2 ml 
DMEM supplemented with heat inactivated 10% (v/v) FBS. Next day, cells were 
transfected with pLKO.1-puro NR4A2 shRNA or non-target control plasmids (Sigma, 
St. Louis, MO) and two helper plasmids (psPAX; Addgene plasmid 12260 and pMD2.G; 
Addgene plasmid 12259, Dr. Trono, Lausanne, Switzerland) using a TransIT-293 
Transfection Reagent (Mirus Bio, Madison, WI) following the protocol recommended 
by the manufacturer. After 6 h, the medium was removed and replaced with fresh 2 ml 
OptiMEM (Invitrogen, Carlsbad, CA) and 10 % (v/v) FBS. At 48 h post-transfection, 
supernatants containing viral particles were collected and filtered with a 0.45 μm PES 
membrane (VWR, Radnor, PA). To transduce DC2.4 cells, the virus particles were 10-
fold diluted in the culture medium and added to the cells in presence of Polybrene 
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(hexadimethrine bromide). After 4 h, the virus particles were removed and the cells were 
cultured in replenished medium until further analysis.  
 
5.2.4 QUANTITATIVE RT-PCR 
At 3 days and 4 days post-transduction, total RNA was isolated using a RNA 
Miniprep kit (Qiagen, Valencia, CA) according to instructions of the manufacturer. The 
primers for analysis of expression levels of NR4A2 gene were designed by using 
PrimerQuest online software (5’-GCACGTCAAAGAACTGGAAAG-3’ and 5’-
TGCCTGCAGGTTAGGAAATAG-3’). qRT-PCR was performed by using a SYBR 
Green iScript one-step RT-PCR kit in a MyiQ single-color real-time PCR detection 
system (BIO-RAD, Hercules, CA). The templates were analyzed in triplicates in 25 μl 
reactions, and 100 ng of total RNA was used for each reaction with the final forward and 
reverse primer concentrations at 0.1 μM each. The average threshold cycles (Ct) 
calculated by the MyiQ optical system software were normalized to average Ct values of 
18S rRNA, and relative changes between the samples were determined. 
 
5.2.5 FLOW CYTOMETRY AND INTRACELLULAR CYTOKINE STAINING  
Changes in TNFα production in response to DMF (solvent control) or indole 
were determined by intracellular cytokine staining (ICS). DC2.4 cells infected with 
NR4A2 shRNA lentiviral particles were transferred into a 96 well U-bottom tissue 
culture plate at 2 days post- transduction, and exposed to indole or DMF overnight (~19 
h). Next day, 5 µg/ml lipopolysaccharide (LPS) (Invivo Gen, San Diego, CA) and 1,000-
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fold diluted GolgiPlug (BD Biosciences, San Jose, CA) were added to the cells for 4 h. 
After two washes in PBSA (PBS supplemented with 0.5% BSA), cells were fixed with 4% 
paraformaldehyde on ice, permeabilized with Perm/Wash buffer (BD Biosciences, San 
Jose, CA) and stained with Alexa Fluor 700 TNFα antibody (BD Biosciences, San Jose, 
CA) for 1 h. The cells were resuspended in PBSA and stored in the dark at 4°C until 
analysis. Unstained or unstimulated cells were used as negative controls. Data were 
acquired on a BD FACSAria II cell sorter system (BD Biosciences, San Jose, CA) and 
analyzed with FlowJo software (Tree Star, Ashland, OR).    
 
5.3 RESULTS 
 
5.3.1 EXPRESSION OF NR4A RECEPTORS IN DC2.4 CELLS 
In an effort to identify a NR4A member involved in recognition and 
inflammatory signaling of indole, we investigated expression levels of NR4A receptors 
in DC2.4 cells. Western blot analysis using an antibody that recognizes NR4A1 or 
NR4A2 receptor showed that expression of NR4A2 was much higher than NR4A1 (Fig. 
5.1). Based on this result, NR4A2 was firstly targeted for a functional study of 
knockdown.  
 
5.3.2 KNOCKDOWN OF NR4A2 BY SHRNA LENTIVIRAL TRANSDUCTION  
After transient lentiviral transduction of NR4A2 shRNA, expression levels of 
NR4A2 mRNA were measured by qRT-PCR to determine a time point for the most 
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efficient knockdown.  At 3 days post-transduction, the NR4A2 mRNA level was reduced 
to 47% of the control. However, the NR4A2 mRNA level increased back up to 88% of 
the control at 4 days post-transduction. Accordingly, all experiments were conducted at 
3 days post-transduction to investigate the impact of NR4A2 knockdown on TNFα 
production.   
 
5.3.3 A ROLE OF NR4A2 ON ANTI-INFLAMMATORY SIGNALING OF 
INDOLE IN DC2.4 CELLS   
Previously, our lab reported that indole exerts anti-inflammatory effects on 
intestinal epithelial cells (IECs) (27). To test if indole exposure alters DC2.4 function, 
we exposed DC2.4 cells to 0.5 mM and 1 mM indole overnight (~ 19 h) before 
stimulation with LPS (1 μg/ml) for 4 h followed by intracellular cytokine staining (ICS) 
and flow cytometry. Similar to the effects on IECs, the indole treatment attenuated the 
fraction of cells that were producing the pro-inflammatory cytokine TNFα (i.e., 13 % 
decrease with 0.5 mM and 29 % decrease with 1 mM indole) (Fig. 5.2A). Control DC2.4 
cells were treated with DMF solvent control. These data demonstrate that indole 
attenuates indicators of inflammation in DC2.4 cells. To explore an involvement of the 
NR4A2 in anti-inflammatory signaling of indole, DC2.4 cells were transduced with 
NR4A2 shRNA lentiviral particles and its effect on TNFα production was investigated at 
3-days post-transduction. As shown in Fig. 5.2B, ~ 53% knockdown of NR4A2 resulted 
in less suppression of TNFα production than the untransduced control (i.e., 3 % decrease    
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Fig. 5.1. Expression of NR4A receptors in DC2.4 cells. The western blot analysis 
was performed in quadruplicate.       
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Fig. 5.2. The NR4A2 knockdown attenuates indole-derived suppression of TNFα 
production in DC2.4 cells. ICS and flow cytometry of TNFα were performed after 
exposure to indole overnight (~ 19 h) followed by stimulation with LPS (1 μg/ml) 
for 4 h. (A) Untransduced cells (B) NR4A2 shRNA lentivirus transduced cells.  
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with 0.5 mM and 14 % decrease at 1 mM indole). From these data, it can be concluded 
that the NR4A2 is important in mediating the anti-inflammatory effects of indole in 
DC2.4 cells.  
      
5.4 DISCUSSION  
Increasing evidence suggests that the metabolites produced by the 
gastrointestinal (GI) tract microbiota are important modulators of human health and 
disease (48, 211). For example, the bacterial metabolite indole has been recently shown 
to strengthen host cell-barrier properties and modulate inflammation by increasing anti-
inflammatory IL-10 and decreasing pro-inflammatory IL-12 and IL-8 cytokines (27). 
Although several microbiota-derived metabolites have been identified and studied for 
their function, in-depth research is required to understand molecular mechanisms 
underlying sensing and signaling of these metabolites.  
Dendritic cells (DCs) play an important role in initiation and maintenance of 
immune responses by helping naïve T cells to develop into effector T-helper (Th) cells. 
Depending on microenvironment and stimuli, DCs produce various cytokines (IL-12, IL-
6, TNFα, IL-10, TGFβ, etc.) that determine type and function of Th cells and thus DCs 
play a critical role in shaping overall immunity (212-214).  In addition to dietary and 
microbial signals, intestinal DCs take microbiota metabolites from intestinal lumen and 
epithelial cell layer to orchestrate function of gut-associated lymphoid tissue (210, 215). 
Due to the diffusible nature of indole (64), we hypothesized that DCs in the Peyers 
patches are exposed to microbiota metabolites such as indole by M-cell transcytosis (206) 
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and these metabolites likely alter production of cytokines by DC’s, thereby, leading to 
modulation of mucosal inflammation. Since indole was previously shown to alter 
production of several inflammatory cytokines in IECs (27), we first tested indole among 
several TRP derivatives to monitor a change of DCs’ production of a pro-inflammatory 
cytokine (i.e., TNFα). As shown in Fig. 5.2A, the indole treatment resulted in a 
significant decrease of in cell population that were expressing TNFα. This result 
demonstrates that indole is recognized by DC2.4 cells and exerts the anti-inflammatory 
effect.        
To elucidate the signaling pathway(s) through which the anti-inflammatory 
effects of indole are mediated in DC2.4 cells, we carried out knockdown of the NR4A2 
nuclear receptor and investigated the resultant effect on DC 2.4 function. NR4A2 is a 
member of the NR4A subfamily of orphan nuclear receptors (132, 147). NR4A receptors 
act as transcription factors, regulating expression of downstream genes in apoptosis, 
proliferation, cell migration, angiogenesis and inflammation (216). Saijo and co-workers 
reported that NR4A2 represses transcription of TNFα and IL-1β in macrophages and 
microglia, and this trans-repression is mediated by recruitment of co-repressor for 
element-1 silencing transcription factor (CoREST) complex to a target promoter and 
clearance of NF-κB (144). Although the NR4A subfamily is known to be operated in a 
ligand independent manner (128), several compounds based on 1,1-bis(3’-indolyl)-1-(p-
substituted phenyl)methanes (C-DIMs)  have been recently identified as agonists for 
NR4A (132, 147). DIM is generated through heterodimerization of indole-3-carbinol in 
the acid environment of the gut (81). Since indole-3-carbinol can be structurally 
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considered as a derivative of the indole, we hypothesized that indole attenuates 
production of TNFα in part through activation of NR4A2. As shown in Fig. 5.2B, 
NR4A2 knockdown resulted in a smaller down-regulation of TNFα upon indole 
exposure as compared to the control. This result demonstrates that activation of NR4A2 
is required for down-regulation of TNFα production by indole in DC2.4 cells. Similar 
results were also obtained in primary DC’s (not shown).  
While knockdown of NR4A2 resulted in a decrease in the indole-mediated 
suppression of TNFα, complete abolishment of TNFα expression was not observed. This 
could be due to low knockdown efficiency (~53%) or due to the presence of additional 
receptors that can bind indole and mediate its effect on inflammatory cytokine 
production.  
An example of a second receptor for indole is the aryl hydrocarbon receptor 
(AhR). The AhR is a ligand-activated transcription factor that plays an important role in 
the intestinal immune system (70, 71). Immunomodulation by AhR activation in DCs 
has been reported in several studies. For example, the AhR agonist benzo(α)pyrene was 
shown to inhibit TNFα secretion by LPS-stimulated mouse bone marrow-derived 
dendritic cells (217). The decrease of TNFα production was likely due to AhR activation 
because the AhR antagonist alpha-naphthoflavone counteracted the effect of 
benzo(α)pyrene. In another study, the well-known AhR agonist TCDD suppressed 
binding of NF-κB/Rel which has been described to be involved in pro-inflammatory 
gene regulation such as IL-6 to its response element and blocked translocation into the 
nucleus in TNFα treated DC2.4 cells (218, 219). Current work in our laboratory is 
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focused on evaluating the effects of AhR knockdown on the indole-mediated down-
regulation of TNFα expression in DC 2.4 cells.   
In summary, we have identified NR4A2 as a nuclear receptor to which indole 
binds to induce changes in TNFα production in DC 2.4 cells. Activation of NR4A2 is 
essential for maximal anti-inflammatory activity of indole in DC2.4 cells. Although 
exogeneous and synthetic ligands for NR4A2 are previously reported, this is the first 
report of a putative endogenous ligand for NR4A2 and provides a new tool for 
modulation of inflammatory disorders.  
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CHAPTER VI 
CONCLUSIONS AND RECOMMENDATIONS 
  
6.1 CONCLUSIONS  
In this work, we have successfully presented a methodology for the systematic 
prediction, identification and quantification of metabolites produced by the intestinal 
microbiota (Chapter III). We predicted tryptophan (TRP) derived metabolites by 
constructing biochemical transformation pathways from candidate bacterial reactions in 
the KEGG database and excluding metabolites which could be formed through host 
metabolism. Among predicted TRP derivatives, the final panel of metabolites (i.e., 
indole, hydroxyindole, indole 3-acetate, indole 3-acetamide, tryptamine, TRP) was 
quantified in murine fecal and cecum extracts using MRM mass spectrometry. To our 
knowledge, this is the first study to use MRM mass spectrometry for absolute 
quantification of microbiota metabolites in murine tissue samples. Additionally, some of 
the identified metabolites (i.e., indole 3-acetate, tryptamine, indole 3-pyruvate) were 
shown to activate AhR signaling, thus suggesting putative biological roles for these 
metabolites. The strength of our methodology is the ability to unambiguously identify 
bacterial metabolites by discriminating host-derived metabolites and quantify their 
physiological levels in the GI tract. This systematic approach is expected to have a 
significant impact on the study of human gut microbiome function and lead to the 
discovery of derivatives of natural compounds generated in the body with biological 
significance that have not previously been investigated.   
 108 
 
We developed an integrated network model of dynamics of key transcription 
factors (i.e., PPAR, C/EBP, CREB, NFAT, FoxO1, SREBP1c) underlying adipocyte 
differentiation and lipid loading (Chapter IV). A hypothetical network model was 
determined based on published connections, and stochastic simulation algorithm was 
applied to simulate random fluctuations of the transcription factors. Transcription factor 
activation profiles were experimentally measured using 3T3-L1 reporter cell lines where 
the binding of a transcription factor to its DNA binding element drives expression of the 
Gaussia luciferase gene. The simulated profiles were consistent with the measured 
profiles, and correctly ordered peak activities of the transcription factors. The model was 
further verified by perturbing the activation level of CREB and determining its effects on 
CREB-downstream transcription factors (i.e., PPAR, C/EBP). The integrated model of 
the transcription factor network developed in this study is expected to provide a 
powerful tool for direct control of the entire regulatory network and a framework for 
manipulating adipocyte metabolism against obesity.  
We investigated the molecular recognition mechanism of indole and its anti-
inflammatory signaling in DC2.4 cells (Chapter V). It was shown that indole suppresses 
the production of pro-inflammatory cytokine, TNFα, upon LPS stimulation. To 
understand how indole exerts the anti-inflammatory effect in DC2.4 cells, a functional 
study of NR4A2 knockdown was performed. The NR4A2 knockdown resulted in less 
suppression of indole on TNFα production. This result indicates that NR4A2 is a 
molecular mediator of indole for the suppression of TNFα production. The finding of 
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indole as a NR4A endogeneous ligand is expected to provide a new strategy for 
treatment of inflammatory disorders.    
 
6.2 RECOMMENDATIONS 
An extension of the methodology described in Chapter III is to predict and 
identify microbiota metabolites which can be derived from different source compounds. 
One such source compound could be phenylalanine of which derivatives have been 
shown to be associated with several diseases such as diabetes and autism. For example, 
phenylacetylglutamine whose precursor, phenylacetic acid is produced by gut bacterial 
metabolism was found in higher concentrations in the plasma of diabetic patients (61) 
and lower levels in urine of autistic children as compared to control (220). The 
methodology can also be applied to identifying bioactive derivatives of environmental 
contaminants such as bisphenol A which was demonstrated to modulate glucose 
transport (221) and increase lipid accumulation in adipocytes (222).   
In the studies of Chapter III and Chapter V, we only focused on regulation of 
bacterial metabolites on host function. In the future work, an interplay model in which 
microbiota metabolites are converted to other compounds by host metabolism can be 
explored to understand comprehensive contribution of microbiota metabolites on human 
diseases. For example, hippurate whose expression levels decrease in urine of autistic 
individuals is formed by hepatic glycine conjugation of dietary and gut microbial-
derived benzoate (223). In liver, gut bacterial metabolite indole is transformed to indoxyl 
by cytochrome P-450, and the indoxyl is further converted to indoxyl sulfate by 
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sulfotransferase (64). The indoxyl sulfate is known to accumulate in the blood of 
patients with chronic kidney failure (65). In this way, co-metabolites generated by host 
enzymes from metabolites produced by the microbiota, could play an important role in 
health and disease. It should be noted that the algorithm presented in Chapter III can be 
modified to predict these co-metabolites by starting with a specific microbiota 
metabolite and constructing host-derived transformation pathways shown in Chapter III.      
Gut microbiota are important factors in obesity and metabolic disorders, but little 
is known about direct influence of microbiota metabolites on adipocyte differentiation 
and inflammation. The integrated transcription factor (TF) network we developed in 
Chapter IV can be used as a platform to investigate how microbiota metabolites 
modulate adipocyte differentiation, lipid accumulation, and inflammation. A strategy for 
this purpose is as follows. First, the TRP derivatives identified in Chapter III are used to 
treat 3T3-L1 TF reporter cells showing the earliest activation (i.e., CREB) or persistent 
activation at a later stage of differentiation process (i.e., PPARγ). After getting TRP 
metabolites-triggered perturbation of CREB or PPARγ profiles, a change in the 
activation of other TFs and of the entire TF network can be determined, as any 
perturbation to the TF network is expected to lead to a change in the expression level of 
target genes which are regulated by these TFs.   
Obesity is characterized by low-grade chronic inflammation and macrophage 
infiltration. To mimic the environment of macrophage infiltration, the spent medium of 
LPS-stimulated macrophage J774A.1 cells can be introduced into the 3T3-L1 adipocyte 
culture medium. In a preliminary study, it was demonstrated that the spent medium of 
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LPS-stimulated J774A.1 cells induced activation of NFAT (data not shown). In addition, 
the binding activity of NFAT was shown to be significantly increased in white adipose 
tissues of obese mice as compared to control (224). Therefore, an increase of the NFAT 
activity by the spent medium of LPS-stimulated J774A.1 cells can be linked to adipocyte 
inflammation during obesity development. A study to investigate whether microbiota 
metabolites are involved in modulation of adipocyte inflammation can be carried out in 
two ways, as TRP metabolites can modulate secretion of pro-inflammatory molecules in 
J774A.1 cells or interfere with pro-inflammatory signaling in 3T3-L1 cells. In the first 
approach, TRP-derived metabolites can be added to the J774A.1 culture medium during 
LPS stimulation to modulate composition of the spent medium. Then, the spent medium 
with altered composition can be used to stimulate 3T3-L1 NFAT reporter cells to 
monitor a change of NFAT activity. In the second approach, 3T3-L1 NFAT reporter 
cells can be exposed to TRP metabolites after introducing spent medium from LPS-
stimulated J774A.1 cells.  
In the functional study of NR4A2 knockdown (Chapter V), it was demonstrated 
that NR4A2 is a molecular mediator of anti-inflammatory signaling of indole. The AhR 
is another attractive target for the knockdown study because several TRP-derived 
metabolites were shown to have ability of AhR activation in our and other reports. If 
knockdown of AhR also attenuates indole-derived suppression of TNFα production, we 
can hypothesize both NR4A2 and AhR participate in sensing of indole for anti-
inflammatory activity. Further, our data in which the NR4A2 knockdown did not 
completely abolish indole-derived suppression of TNFα production support a possibility 
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that the anti-inflammatory activity is an output of the sum of several mechanisms. 
Simultaneous knockdown of NR4A2 and AhR is expected to provide information on the 
extent to which the different pathways are involved in indole-mediated suppression of 
cytokine production in DC 2.4 cells. For other TRP derivatives which may show indole-
like behavior, a similar approach can be applied to identify mechanisms involved in 
mediating their anti-inflammatory functions.  
Together, these strategies and experiments can provide fundamental 
understanding of the interaction between intestinal microbiota and mucosal host 
interactions cells, which can in turn lead to the development of novel treatment strategies 
and modalities against obesity and gastrointestinal inflammation. 
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